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Abstract 
 
STUDIES ON THE ROLE OF THE N-TERMINAL DOMAIN OF NR1 IN THE 
REDOX MODULATION OF NR2A-CONTAINING NMDA RECEPTORS 
 
Greta Ann Herin, PhD 
 
University of Pittsburgh, 2003 
 
 
The NMDA receptor is the subject of intense study due to its critical role in 
many neuronal processes and neuropathologies.  This receptor is modulated by 
a wide variety of endogenous and exogenous agents, including reducing and 
oxidizing (redox) agents.  Despite a wealth of physiological information, details of 
the structural basis of modulation are only beginning to emerge.  It has been 
proposed that the amino terminal domain (ATD) of NMDA receptor subunits may 
serve as a modulatory domain, as several agents appear to have sites of action 
in this region of the receptor.  NR1/NR2A receptors contain cysteines in the ATD 
of both NR1 and NR2 that confer unique redox sensitivity to these receptors; 
however, the ATD redox sensitivity of NR1/NR2A receptors remains largely 
unexplored.  The goal of this dissertation was to explore the impact of reducing 
and oxidizing agents on NMDA receptor function, focusing on the amino terminal 
domain redox sites.  Here we demonstrate that a clinically efficacious 
neuroprotective agent, ebselen, is active as an oxidizing agent of the NMDA 
receptor.  Additionally, these studies demonstrate a novel modulation of 
NR1/NR2A redox mutants by the polyamine spermine and explore a relationship 
between redox and spermine modulation of NR1/NR2A mutant receptors. 
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1. Introduction 
1.1. Composition of NMDA receptors 
 Ionotropic glutamate receptors (iGluRs) mediate excitatory 
neurotransmission in the central nervous system through the ligand-induced 
opening of ion channels (reviewed in Dingledine et al., 1999; McBain and Mayer, 
1994) .  Activation of the NMDA subtype of iGluR has been linked to long-term 
potentiation and depression, as well as neuronal development (Dingledine et al., 
1999).  Additionally, overactivation of the NMDA receptor is a well-documented 
causative factor in pathological processes such as ischemia-induced 
excitotoxicity (Lee et al., 1999) and seizures (Loscher, 1998).  Therefore, there is 
great scientific and clinical interest in elucidating NMDA receptor structure-
function relationships in order to develop novel pharmaceutical strategies aimed 
at modifying NMDA receptor activity.  
 Despite intense investigation, many questions remain unanswered 
regarding NMDA receptor composition, structure, and the molecular mechanisms 
of gating and modulation.  NMDA receptors are most likely tetramers (Schorge 
and Colquhoun, 2003).  The best studied of the NMDA receptors are those 
composed of NR1 and NR2 subunits. Cloning of NMDA receptor subunits has 
revealed that the NR1 subunit is a single gene product that has at least eight 
splice variants, a-h, while the NR2 subunits are the products of four different 
genes NR2A-NR2D (McBain and Mayer, 1994).  Differential expression of NR1 
splice variants and NR2 subunits occurs spatially and developmentally, 
conferring temporal and regional specificity of NMDA receptor composition 
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(Monyer et al., 1994; Paupard et al., 1997; Prybylowski et al., 2001). In addition 
to NR1 and NR2 subunits, the NR3 subunit has been cloned and studied in 
heterologous expression systems, and may form receptors with unique 
properties, albeit yet to be extensively characterized (Al-Hallaq et al., 2002; 
Matsuda et al., 2002; Perez-Otano et al., 2001) .   
 NMDA receptor subunit and splice variant composition determines the 
sensitivity of receptors to modulation by a wide variety of compounds.  
Exogenous agents such as ifenprodil (Masuko et al., 1999; Williams, 1993), and 
cyanide (Arden et al., 1998) have subunit-specific actions on NMDA receptors.  
More importantly, endogenous agents modulate NMDA receptors at physiological 
ranges and in a subunit-specific manner (McBain and Mayer, 1994).  These 
modulatory agents include protons (Traynelis et al., 1995), polyamines (Williams, 
1997b), zinc (Paoletti et al., 1997; Zheng et al., 2001), and sulfhydryl reducing 
and oxidizing agents (Aizenman, 1994; Brimecombe et al., 1997).  
 Homology modeling (Fayyazuddin et al., 2000; Masuko et al., 1999; 
Zheng et al., 2001) and structural studies (Armstrong et al., 1998; Furukawa and 
Gouaux, 2003; Jin et al., 2003; Jin et al., 2002) reveal ionotropic glutamate 
receptor subunits to be modular proteins (Figure 1; Wo and Oswald, 1995).  
There appear to be discrete ligand binding domains which also bind competitive 
antagonists such as 5,7-dichlorokyurenate (DCK; Furukawa and Gouaux, 2003) 
and L(+)-2-Amino-5-phosphonopentanoic acid (L-AP5; Tikhonova et al., 2002).  It 
appears that a pore forming domain in which channel blockers such as Mg 
(Wollmuth et al., 1998a; Wollmuth et al., 1998b) and MK-801 (Elhallaoui et al., 
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2002) bind and inhibit NMDA mediated responses, and an amino terminal 
domain which has been called a "regulatory domain" by some groups to show 
that this domain appears to be an important site of binding for allosteric 
modulators (Masuko et al., 1999). 
Amino Terminal
Domain
Ligand Binding
Domain
Pore Forming
Domain
Carboxyl Terminal
Domain
 
Figure 1. Schematic of NMDA receptor subunit putative domain 
structure. 
Schematic adapted from (Zheng et al., 2001).  NMDA receptor subunits appear 
to be modular proteins with functional domains.  The amino terminal domain 
(approximately 400 amino acids), ligand-binding domain, pore-forming domain, 
and carboxyl-terminal domain are illustrated. 
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1.2. Modulation of NMDA receptor-mediated responses by redox agents 
1.2.1. The ligand binding domain-associated redox site of NR1 
 Physiological responses in neurons mediated by NMDA receptors are 
potentiated by disulfide reducing agents such as dithiothreitol (DTT; Aizenman et 
al., 1989; Tang and Aizenman, 1993b).  Conversely, sulfhydryl oxidants such as 
5,5’-dithio-bis(2-nitrobenzoic acid) (Aizenman et al., 1989; Brimecombe et al., 
1997), lipoic acid (Tang and Aizenman, 1993a), and pyrroloquinoline quinone 
(PQQ; Aizenman et al., 1992) are able to reverse DTT potentiation.  Oxidants 
can also depress NMDA receptor function from baseline levels, depending on the 
native redox state of the protein (Aizenman et al., 1989; Colton et al., 1989; 
Gozlan and Ben-Ari, 1995; Sinor et al., 1997).  Indeed, it was demonstrated that 
PQQ, previously shown to be neuroprotective in vitro and in vivo (Aizenman and 
Reynolds, 1992; Jensen et al., 1994), was able to reverse the chemical reduction 
of the NMDA receptor redox site that occurred as a result of seizure activity 
(Sanchez et al., 2000).  
 In heterologous systems, NMDA receptors containing the NR1 subunit 
and either the NR2B, NR2C, or NR2D subunits are rendered relatively insensitive 
to potentiation by reducing agents when NR1a cysteines 744 and 798 are 
mutated (Sullivan et al., 1994).  A high resolution crystal structure of the NR1 
ligand-binding domain reveals a hinged clamshell-like structure that closes upon 
ligand binding (Furukawa and Gouaux, 2003).  Cysteines 744 and 798 of NR1 
are located at the hinge of the cleft of NR1, and therefore, Furukawa and Gouaux 
(2003) postulate that the oxidation state of the disulfide bond in the NMDA 
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receptor determines the flexibility of the hinge.  The degree of closure of the 
ligand-binding clamshell correlates with the activity of the channel (Jin et al., 
2003).  Hypothetically, when NMDA receptor disulfide bond c744-c798 is 
oxidized, the flexibility of the ligand-binding hinge is decreased, and closure of 
the clamshell domain is inhibited.  Conversely, in the absence of the disulfide 
bond, the constraint is relieved, and the clamshell closes more fully.  
 
1.2.2. The Amino Terminal Domain-associated redox sites 
 Although redox sensitivity is nearly abolished when the mutant NR1 
subunit NR1a(c744a,c798a) is co-expressed with NR2B,NR2C, and NR2D 
receptors, NR1a(c744a,c798a)/NR2A receptors remain sensitive to reducing 
agents to the same extent as that of wild-type NR1a/NR2A receptors 
(Brimecombe et al., 1999; Kohr et al., 1994).  Choi et al. (2001) demonstrated 
that the remaining DTT sensitivity of NR1a(c744a,c798a)/NR2A NMDA receptors 
is attributable to cysteines in the N-terminal domains of both NR1a(c79,c308) 
and NR2A(c87,c320).  Mutation of all six of these cysteines renders NR1/NR2A 
receptors insensitive to modulation by DTT and the oxidizing agent DTNB (Choi 
et al., 2001).  This implies that that cysteines NR1a(c79,c308) and NR2A(c87, 
c320) dominate redox sensitivity in wild-type NR1/NR2A receptors. 
 
1.3. Modulation at the ATD domain of NMDA receptor subunits 
 Interestingly, the amino terminal domain (ATD) of glutamate receptor 
subunits bears a weak homology to the bacterial amino-acid binding protein 
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leucine-isoleucine-valine binding protein (LIVBP), which has a clamshell-like 
structure analogous to the ligand binding domain (Sutcliffe et al., 1996).  
Modeling and mutagenesis studies have suggested that several modulatory sites 
are located in the ATD domain. For example, fast desensitization of NMDA 
receptors is present only in NR1/NR2A recombinant receptors (Zheng et al., 
2001).  The molecular basis of this desensitization was linked to a high affinity 
zinc binding site in the ATD in the NR2A subunits (Krupp et al., 1998).  There is 
an allosteric interaction between the zinc binding site in the ATD and the 
glutamate binding site such that glutamate binding results in a higher affinity of 
the receptor for zinc (Zheng et al., 2001).  Residues that bind zinc in the ATD 
domain of the NR2A subunit are arranged facing each other across a central 
cleft, and cysteines engineered into the inside of the cleft are inaccessible to 
modification by the cysteine modifying agent 2-trimethylammonioethylmethane 
thiosulfonate (MTSET) in the presence of zinc (Paoletti et al., 2000).  This 
suggests that zinc binding in the cleft of this domain induces a molecular 
"motion" that transduces the allosteric effect of zinc. 
 Phenylethanolamines such as ifenprodil inhibit NMDA responses in an 
NR2B-specific manner (Dingledine et al., 1999) .  Data suggest that the ifenprodil 
binding site may be located in the ATD domain of NR2B (Paoletti et al., 2000; 
Perin-Dureau, 2001; Perin-Dureau et al., 2002; but see Masuko et al., 1999).  
Ifenprodil produces desensitization of NR1/NR2B receptors in a manner that is 
analogous to zinc-induced desensitization of NR1/NR2A receptors (Zheng et al., 
2001).  Mutagenesis studies based on the sequence alignment of NR2B and 
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LIVBP reveal that residues critical to ifenprodil inhibition are located in the cleft of 
the clamshell-like domain (Perin-Dureau, 2001; Perin-Dureau et al., 2002).  This 
evidence regarding zinc and ifenprodil is highly suggestive that binding of 
modulatory compounds to the ATD induces a conformational change that 
allosterically affects the ligand binding domain and ultimately the gating 
mechanism (Masuko et al., 1999; Paoletti et al., 2000; Perin-Dureau et al., 2002; 
Zheng et al., 2001). 
 Although ligands for ATD domains in NR2A and NR2B have been 
suggested, potential modulatory agents that bind to the analogous region of NR1 
are controversial.  A potential ligand of the ATD-domain of NR1 is the 
endogenous polyamine spermine.  Spermine has several effects on the NMDA 
receptor (Williams, 1997b).  These include voltage-dependent channel block at 
high concentrations of spermine as well as current enhancement due to an 
increase in the affinity of the receptor for glycine.  At low concentrations of 
spermine (3-100 µM) and saturating concentrations of glycine, an additional 
enhancement of NMDA-induced currents is observed in NR1/NR2B receptors, 
simply referred to as spermine potentiation (Williams, 1997b).  Mutation of 
residues in the N-terminus of NR1 that block spermine potentiation, 
concomitantly decreases proton inhibition (Masuko et al., 1999; Williams, 1997b).  
This is in agreement with earlier work demonstrating pharmacologically that 
spermine potentiation of NR1/NR2B receptors was via relief of proton inhibition 
(Traynelis et al., 1995). 
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 Interestingly, NMDA-mediated currents are inhibited by protons with an 
IC50 that corresponds to physiological pH (Traynelis and Cull-Candy, 1990; 
Traynelis and Cull-Candy, 1991). This implies that variations in extracellular pH 
not only can have a profound effect on NMDA receptor function per se, but can 
also dramatically alter pH-dependent modulation of the receptor by polyamines 
and other modulatory agents.  Recent studies have suggested that the structural 
components of pH sensitivity are localized very close to the putative gate in NR1 
and NR2 subunits (Low et al., 2003). This might explain the common pH 
dependence of many agents that act at the ATD of NMDA receptor subunits. 
Potentially, conformational changes in the ATD may be allosterically linked to 
gating through a pH sensitive structural element.  
 Splice variants of the NR1 subunit that contain the 21-amino acid insert 
exon 5 (NR1b) are not inhibited as strongly by protons (Traynelis et al., 1995).  
Exon 5 contains several positively charged residues that may resemble the 
structure of spermine (Traynelis et al., 1995).  Additionally, a model of the 
predicted secondary structure of NR1, based on the structure of LIVBP, places 
two residues critical for spermine potentiation (e181,e185) very close to the site 
of the exon 5 insert, supporting the evidence that exon 5 masks or constitutively 
occupies a spermine binding site in the NR1 ATD domain.  
 A growing body of work reveals that modulators of NMDA receptor 
function acting at ATD modulatory sites have pleiotropic allosteric interactions 
with each other.  Zinc inhibits NR1/NR2A receptors at very low concentrations by 
enhancing proton inhibition (Choi and Lipton, 1999; Low et al., 2000; Paoletti et 
 18 
al., 2000; Zheng et al., 2001).  Amino acid substitutions in the cleft of the ATD 
domain of NR2A that most strongly affect zinc binding are also critical to pH 
dependency of zinc inhibition (Low et al., 2000).  This implies that the zinc 
binding domains may interact functionally and/or structurally with the putative 
proton sensor.  
 It is believed that ifenprodil and derivatives bind to the cleft of the ATD 
domain of NR2B (Perin-Dureau, 2001) and enhance proton inhibition of the 
receptor (Mott et al., 1998).  Additionally, there appears to be a negative 
allosteric interaction between ifenprodil and spermine, such that binding of 
spermine to the NMDA receptor results in a reduction of affinity for ifenprodil 
(Kew and Kemp, 1998).  It is worthy to note that concentrations of spermine (1 
and 3 mM) used in the Kew and Kemp (1998) study have been shown to inhibit 
NMDA receptors in a voltage-dependent manner (Williams, 1997b).  Therefore it 
is unclear whether the actions of spermine in this study are due to the binding of 
spermine to a site in the ATD domain, in the channel pore itself, or due to an 
unspecified mechanism.  However, Mott et al., (1998) show that the presence of 
100 µM spermine reduced inhibition of NR1/NR2B receptors by the ifenprodil 
analogue CP101,606 by 44-fold.   
 Several themes emerge from examination of ATD-associated modulation 
of the NMDA receptor.  (1) Inhibitory agents such as zinc and ifenprodil produce 
an incomplete block of receptor function.  This may be because their site of 
action is remote from the ligand-binding domains and the gating element, and 
therefore these agents have an allosteric mechanism of action.  (2) Inhibition by 
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protons is integral to modulation by ifenprodil, spermine, and zinc.  It is likely that 
each of these agents is acting upstream of a proton-sensitive element at or near 
the gate of the channel.  (3) Most modulatory agents display subunit specificity.  
Zinc inhibition is present only in NR1/NR2A receptors. Ifenprodil inhibition is 
present only in NR1/NR2B receptors, and glycine independent spermine 
potentiation has previously only been observed in this receptor configuration.  (4) 
There are numerous interactions between modulatory sites within the ATD 
domain, suggesting that macroscopic effects of NMDA receptor modulation may 
reflect the composite contributions of several different modulatory sites.  
1.3.1. Interaction between redox modulation and other modulatory agents 
 Mutagenesis studies suggest that residues important for redox modulation 
of NMDA receptors are also required for modulation of NMDA receptors by other 
agents.  This is suggestive of an allosteric interaction between redox sensitive 
moieties and other modulatory sites within the ATD region.  There are several 
properties of NMDA receptor redox site mutants that support this hypothesis.  For 
example: The NR1a(c79s,c308s,c744a,c798a)/NR2A(c87a,c320a) mutation 
lacks high affinity zinc block (Choi et al., 2001).  Mutation of each of the putative 
cysteine pairs has a cumulative effect on zinc inhibition (Choi et al., 2001).  This 
implies at least two possibilities: First, that the redox sites of the ATD domain 
have an effect on the allosteric modulation of NR1/NR2A receptors by zinc.  
Second, redox modulation of each subunit does not necessarily impact solely the 
conformation of its own domain, i.e., if zinc binds to the ATD of NR2A, and the 
NR2A ATD domain cysteines allosterically modulate zinc binding in the same 
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domain, then one would predict that NR2A(c87a,c320a)-containing receptors 
would be far less modulated by zinc than NMDA receptors containing other 
cysteine mutations.  This is not the case, implying that the redox state of each 
redox "site" has a more global allosteric effect. (Choi et al., 2001). 
 Additional studies of redox mutants suggests allosteric interactions 
between redox sites and other modulatory sites.  Mutation of the ligand-binding 
domain redox site residues in the relatively redox insensitive 
NR1a(c744a/c798a)/NR2B receptor abolishes spermine potentiation and proton 
inhibition (Sullivan et al., 1994).  Mutation of c744 and c798 on NR1 also 
decreases ifenprodil inhibition in NR1/2B receptors (Mott et al., 1998). 
 Several thorough studies have been performed to elucidate the molecular 
mechanisms of NMDA receptor modulation by zinc, ifenprodil, spermine, exon 5, 
and protons at the ATD domains on NMDA receptor subunits (Masuko et al., 
1999; Paoletti et al., 2000; Zheng et al., 2001).  The presence of redox sensitive 
cysteines in the same domain has been suggested (Choi and Lipton, 1999), 
however, very little is known regarding the impact of reducing and oxidizing 
agents on the ATD domains in NR1/NR2A receptors, and possible interactions 
among ATD cysteines and other modulatory agents of NMDA receptors.  The 
studies contained herein characterize the actions of an exogenous redox 
modulator of NMDA receptor, in addition to studies aimed at determining 
potential structural features of redox modulation of NR1/NR2A NMDA receptors. 
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2. Oxidation of NMDA receptors by the anti-oxidant drug ebselen 
2.1. Abstract 
 Ebselen is a seleno-organic compound currently in clinical trials for the 
treatment of ischemic stroke and subarachnoid hemorrhage.  Its putative mode of 
action as a neuroprotectant is via cyclical reduction and oxidation reactions, in a 
manner akin to glutathione peroxidase.  For this reason, we have investigated 
the effects of ebselen on the redox-sensitive NMDA receptor.  We have found 
that ebselen readily reversed dithiothreitol (DTT) potentiation of NMDA-mediated 
currents in cultured neurons and in Chinese hamster ovary (CHO) cells 
expressing wild-type NMDA NR1/NR2B receptors.  In contrast, ebselen was 
unable to modulate NMDA-induced currents in neurons previously exposed to 
the thiol oxidant 5,5’-dithio-bis(2-nitrobenzoic acid) (DTNB), or in CHO cells 
expressing a mutant receptor lacking the NR1 redox modulatory site, suggesting 
that ebselen oxidizes the NMDA receptor via this site.  In addition, ebselen was 
substantially less effective in modifying NMDA responses in neurons exposed to 
alkylating agent n-ethylmaleimide (NEM) following DTT treatment.  Ebselen also 
reversed DTT inhibition of carbachol-mediated currents in Cos-7 cells expressing 
the αβγδ subunits of the acetylcholine receptor, an additional redox-sensitive ion 
channel.  Ebselen was observed to significantly increase cell viability following a 
30 min NMDA exposure in cultured neurons.  In contrast, other more typical 
antioxidant compounds did not afford neuroprotection in a similar paradigm.  We 
conclude that ebselen may be neuroprotective in part due to its actions as a 
modulator of the NMDA receptor redox modulatory site.  
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2.2. Introduction 
 Ebselen (2-phenyl-1, 2-benzisoselenazol-3[2H]-one) is a seleno-organic 
compound that has been shown to be cytoprotective in various ischemia-
reperfusion models in both heart (Maulik et al., 1998) and brain (Takasago et al., 
1997).  Ebselen is currently in clinical trials for the treatment of ischemic stroke 
(Yamaguchi et al., 1998) and aneurysmal subarachnoid hemorrhage (Saito et al., 
1998).  Although generally considered to be an antioxidant, ebselen is not a free 
radical scavenger per se, but mimics the enzyme glutathione peroxidase (Mueller 
et al., 1984; Sies, 1993; Wendel et al., 1984) and a closely related enzyme, 
phospholipid hydroperoxide glutathione peroxidase (Maiorino et al., 1988).  
Ebselen, like these enzymes, acts with glutathione through a selenium core to 
eliminate hydroperoxides and lipoperoxides.  Although the mechanism of ebselen 
is similar to these macromolecules, ebselen does not have a substrate-binding 
site, and therefore, has a much wider range of specificity (Schewe, 1995; Sies, 
1993).  Importantly, ebselen can interact with cysteine residues contained in 
proteins such as metallothionein (Jacob et al., 1998), glutathione-S-transferase, 
(Nikawa et al., 1994), and the IP3 receptor (Dimmeler et al., 1991), leading to 
thiol oxidation and formation of disulfides and an ebselen diselenide product 
(Schewe, 1995). 
 Several ligand-gated ion channels contain labile cysteine residues that are 
modified by redox-active compounds.  These include the nicotinic acetylcholine 
receptor (Karlin and Bartels, 1966), the GABAA receptor (Pan et al., 1995), and 
the NMDA subtype of glutamate receptor (Aizenman et al., 1989; Tang and 
Aizenman, 1993b).  Of these, a physiological role for redox modulation has been 
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evaluated extensively on the NMDA receptor (Aizenman, 1994; Aizenman et al., 
1998), due to the importance of this protein in such processes as neuronal 
development, learning and memory, and excitotoxicity (Dingledine et al., 1999).  
Physiological responses in neurons mediated by NMDA receptors are 
potentiated by disulfide reducing agents such as DTT (Aizenman et al., 1989; 
Tang and Aizenman, 1993b).  Conversely, sulfhydryl oxidants such as 5,5’-dithio-
bis(2-nitrobenzoic acid) (Aizenman et al., 1989), lipoic acid (Tang and Aizenman, 
1993a), and PQQ (Aizenman et al., 1992) are able to reverse DTT potentiation.  
Oxidants can also depress NMDA receptor function from baseline levels, 
depending on the native redox state of the receptor (Aizenman et al., 1989; 
Colton et al., 1989; Gozlan et al., 1994; Sinor et al., 1997).  Indeed, it was 
recently demonstrated that PQQ, previously shown to be neuroprotective in vitro 
and in vivo (Aizenman et al., 1992; Jensen et al., 1994), was able to reverse the 
chemical reduction of the NMDA receptor redox site that occurred as a result of 
seizure activity (Sanchez et al., 2000).  This condition appeared to induce the 
release of yet unidentified endogenous reducing agents (Sanchez et al., 2000).  
As ebselen can alter the function of various proteins via thiol oxidation, we 
investigated whether this drug could also interact with the redox-sensitive NMDA 
receptor to modulate its function.  Such an interaction would be suggestive of a 
novel mechanism of ebselen in altering glutamatergic synaptic transmission and 
associated pathophysiologies. 
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2.3. Materials and Methods 
2.3.1. Tissue Culture 
 Cortical neurons were dissociated from E16 Sprague-Dawley rats as 
described previously (Hartnett et al., 1997).  Cortices were dissociated in Earle’s 
balanced salt solution (EBSS) with 0.03% trypsin at 37°C.  Plating suspension 
was adjusted to a density of 335,000 cells/ml growth media.  Growth media 
contained 80% (v/v) Dulbecco’s Modified Eagle Medium (DMEM; Gibco BRL, 
Rockville, MD) with 10% heat-inactivated, iron-supplemented bovine calf serum 
(Hyclone, Logan, UT), 10% Ham’s F-12 media (Sigma), 25 mM HEPES, 24 U/ml 
penicillin, 24 U/ml streptomycin, and 2 mM L-glutamine.  Dissociated cells were 
plated in 6-well plates containing five 12 mm glass coverslips that had been 
previously treated with poly-L-lysine.  Cells were refed on a Monday-Wednesday-
Friday basis and maintained in 37°C, 5% CO2.  Two weeks after plating, non-
neuronal cell growth was arrested with a 72-hour treatment with 2 µM cytosine 
arabinoside, after which the growth media contained only 2% serum and no F-12.  
Cells were used for electrophysiology experiments in the fourth week after 
dissociation.  
 For toxicity experiments, forebrain neuronal-enriched cultures were 
prepared as previously described (Aizenman et al., 2000).  Dissociated cells from 
E17 rat fetuses were plated on poly-L-ornithine-treated tissue culture plates in a 
growth medium containing 80% DMEM (high glucose with L-glutamine and 
without sodium pyruvate; Gibco BRL), 10% Ham’s F-12 nutrients, and 10% heat-
inactivated bovine calf serum, and 1x anti-mycotic/anti-biotic mixture with 
amphotericin B and streptomycin sulfate (Gibco BRL).  Cultures were maintained 
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at 37°C in 5% CO2.  Glial cell proliferation was inhibited after 48 hours in culture 
with 1-2 µM cytosine arabinoside.  Serum-containing medium was replaced after 
three days in vitro with a serum-free medium containing Neurobasal medium 
(without L-glutamine; Gibco BRL), B27 supplement (Gibco BRL), and anti-
mycotic/anti-biotic mixture as above.  
 
2.3.2. Heterologous Expression Systems  
 Chinese hamster ovary (CHO) cells were grown in Ham’s F-12 media 
containing 10% Fetal Bovine Serum (FBS) and 2 mM L-glutamine.  Cells were 
passaged (less than 30 times) at a 1:10 dilution when 80% confluent, usually 
every two days.  The cDNAs for NMDA receptor subunits had been previously 
ligated into mammalian expression vectors containing the cytomegalovirus 
promoter (Boeckman and Aizenman, 1996; Brimecombe et al., 1999).  CHO cells 
were seeded at 2.8x105 cells/well into 6-well plates 24 hours previous to 
transfection.  Cells were transfected in serum-free medium with 6 µL 
LipofectAMINE reagent (Gibco BRL) and a total of 1.4 µg of DNA/well.  A ratio of 
0.3:1:3 Green Fluorescent Protein: NR1: NR2 subunit ratio was employed.  Four 
hours after transfection, cells were refed with media containing 10% serum, and 
24 hours or less after transfection, 300 µM ketamine was added to prevent the 
excitotoxic cell death that occurs following functional receptor expression 
(Boeckman and Aizenman, 1996). 
 Cos-7 cells were maintained in DMEM containing 10% FBS and 2 mM L-
glutamine and were passaged at a 1:5 dilution at 70-80% confluency, 
approximately every two days.  Acetylcholine receptor subunit (α, β, δ and ε) 
 26 
cDNA in pSM with an SV40 promoter was the kind gift of Dr. Zuo-Zhong Wang 
(University of Pittsburgh School of Medicine, Pittsburgh, PA).  Cos-7 cells were 
transiently transfected with the following subunit ratios: 1.32 alpha: 0.66 beta: 
0.32 delta: 1.00 epsilon.  The transfection protocol was similar to that described 
for CHO cells, without the ketamine addition.  Cells were used for recording 40-
60 hours after transfection (Gu et al., 1990). 
2.3.3. Electrophysiology 
 Electrophysiological recordings were performed at room temperature 
(25°C) using the whole-cell configuration of the patch-clamp technique.  Cells 
were bathed in external solution containing (in mM): 150 NaCl, 1.0 CaCl2, 2.8 
KCl, 10 HEPES, 10 glycine, 25 tetrodotoxin (Calbiochem, La Jolla, CA) and pH 
was adjusted to 7.2 with NaOH.  Electrodes were pulled on a Sutter P-87 
electrode puller (Sutter Instruments, Novato, CA) to a resistance of 1.5-3 MΩ 
when filled with internal solution containing (in mM): 140 CsF, 10 EGTA/CsOH, 1 
CaCl2, and 10 HEPES (pH adjusted to 7.2 with CsOH).  Signals were amplified 
using an Axopatch 200B integrating patch-clamp amplifier (Axon Instruments, 
Foster City, CA), filtered using an 80 dB/decade filter at 1 kHz, and digitized at 2 
kHz with a DigiData 1200b (Axon Instruments) computer interface.  The 
reference electrode was an Ag/AgCl wire bridged with 2M KCl/1% agarose in PE-
90 tubing.  Drugs were applied via a perfusion system with a stepper motor for 
fast solution changes (Warner Instruments Corp., Hamden, CT).  NMDA, DTT, 
DTNB, NEM and ebselen (Sigma Chemical Company, St. Louis, MO) were all 
dissolved in external solution for recording.  Ebselen was diluted from a 50 mM 
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stock solution in DMSO. Data were collected and analyzed using commercially 
available software (pCLAMP 8, Axon Instruments). 
2.3.4. Toxicity Assays 
 Coverslips containing forebrain neurons were transferred from 6-well 
plates to 24-well plates and treated in triplicate.  Coverslips were maintained in 
serum-containing media at 37°C until ready for treatment.  Cells were gently 
washed twice with 2 ml of a solution containing minimum essential media (MEM; 
no phenol red), 0.01% bovine serum albumin (BSA; Sigma), and 25 mM HEPES 
(MEM/BSA).  Drugs were diluted in 1 ml MEM/BSA, and wells were incubated in 
treatment solutions for the indicated period of time.  After treatment, cells were 
washed as before.  Cells were incubated for 20 hours in MEM/BSA, at which 
point neuronal viability was measured with a lactate dehydrogenase (LDH) -
based in vitro toxicology assay kit (Sigma; Hartnett et al., 1997).  Media samples 
(40 µL) were analyzed spectrophotometrically (490:630 nm) according to the 
manufacturer’s protocol, to obtain a measure of cytoplasmic LDH release from 
dead and dying neurons.  Relative toxicity is expressed in optical density (O.D.) 
units.  
2.4. Results 
2.4.1. Ebselen modifies NMDA receptor function 
 Whole-cell responses to 30 µM NMDA were recorded at –60 mV under 
control conditions, after a 3-min application of 4 mM DTT, and following a 30-sec 
incubation in varying concentrations of ebselen.  Ebselen was able to readily 
reverse DTT-mediated NMDA current potentiation in a concentration-dependent 
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manner (Figure 2A).  At higher concentrations of ebselen (10-30 µM), post-
ebselen currents were sometimes smaller than control responses (i.e. before 
DTT treatment).  Cells were treated further with repeated iterations of this 
protocol; DTT and ebselen were able to exert opposing effects on each cell for as 
long as the recording configuration was held.  Furthermore, the effects of ebselen 
in depressing NMDA-induced currents could only be reversed by an additional 
DTT treatment.  This effect of ebselen closely resembles the actions of the 
oxidizing agent DTNB (Aizenman et al., 1989; Tang and Aizenman, 1993b), 
implying that ebselen is able to oxidize the redox site of the NMDA receptor.  We 
noted that incubations with ebselen at concentrations in the 100-300 µM range 
quickly destabilized the recordings.  Therefore, we were unable to determine 
whether this compound could oxidize the NMDA receptor to the same extent as 
DTNB (500 µM; Figure 2B).  Nonetheless, pre-treatment with DTNB (500 µM) 
occluded any potentially additional actions of ebselen (30 µM), further 
strengthening the notion that the seleno-organic compound acts via the NMDA 
receptor redox site (Figure 2C).    
 An additional set of experiments confirmed that ebselen did not alter 
membrane conductance by itself or directly antagonize NMDA responses.  No 
currents were observed during a 2 min application of 10 µM ebselen (not shown).  
In addition, 10 µM ebselen co-applied during application of 30 µM NMDA did not 
appreciably alter whole cell responses (Figure 3).   
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Figure 2. Ebselen reverses NMDA-induced whole-cell current 
potentiation by the reducing agent DTT. 
A: Representative whole-cell recordings from a cortical neuron during activation 
by 30 µM NMDA at –60 mV.  Cells were bathed in 4 mM DTT for 3 min, which 
potentiated NMDA currents by an average of two-fold.  Immediately following 
DTT, cells were treated with 10 µM ebselen for 30 sec, reversing the actions of 
DTT.  Bar depicting NMDA application is only shown in the first trace in this and 
subsequent figures for clarity.  B: Whole-cell responses to 30 µM NMDA from a 
cell previously exposed to 4 mM DTT, and following a 30 s exposure to 500 µM 
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DTNB, and following a wash period, to an additional 30 s treatment with 30 µM 
ebselen.  Note that ebselen does not alter the amplitude of the currents after 
prior oxidation with DTNB.  Similar observations were made in a total of 6 cells.  
C: Reversal of DTT potentiation is concentration dependent.  Each bar of the 
histogram represents the mean ratio (± S.E.M. n=4 to 8) between the peak 
potentiated current (3 min DTT) and the peak current after 30 sec treatment with 
wash, ebselen, or 500 µM of the oxidizing agent DTNB.  A Kruskal-Wallis test 
revealed a significant treatment effect by ebselen (p< 0.05).  Controls utilizing the 
maximal concentration of DMSO used (0.06%) had no effect on the currents. 
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Figure 3. Ebselen does not directly antagonize NMDA receptors. 
A: NMDA (30  µM)-induced current elicited from a 4-week old cortical neuron.  B: 
When 10 µM ebselen was applied for 4 sec during application of NMDA, ebselen 
did not alter whole cell responses to agonist.  Similar results were obtained in a 
total of 5 cells. 
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2.4.2. Ebselen is unable to modulate NR1a(c744a,c798a)/NR2B receptors 
 To confirm that ebselen reversed the actions of DTT in neuronal receptors 
by oxidizing the known redox-sensitive site on the NR1 subunit (Sullivan et al., 
1994), we transiently expressed cDNAs for both wild-type (NR1/NR2B) and a 
redox-insensitive double cysteine mutant (NR1a(c744a, c798a)/NR2B; 
Brimecombe et al., 1999; Sullivan et al., 1994) NMDA receptor in CHO cells.  
Currents recorded from cells expressing NR1/NR2B NMDA receptors showed 
properties similar to those obtained from cultured neurons.  DTT potentiation was 
approximately 1.5-2 -fold, and a 30-sec application of ebselen (10-30 µM) 
reversed this potentiation (Figure 4A).  However, in NR1a(c744a,c798a)/NR2B 
expressing cells, little or no DTT potentiation was observed, and ebselen did not 
appreciably alter the magnitude of currents (Figure 4B).  The lack of effect of 
ebselen in this redox-insensitive NMDA receptor configuration strongly implicates 
cysteines 744 and 798 in the modulation of NMDA receptor function by this 
compound.  In an additional set of studies, we incubated neurons with the 
alkylating agent NEM (300 µM) immediately following a 6 mM DTT treatment.  
Under these conditions, we have previously shown that the NMDA receptor can 
be alkylated and rendered relatively insensitive to further reduction or oxidation 
(Tang and Aizenman, 1993b).  Following alkylation, the actions of ebselen in 
modulating NMDA receptor function were dramatically diminished (Figure 4C).  
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Figure 4. Modulation of NMDA currents by ebselen requires a functional 
redox site. 
A: Representative whole cell currents recorded from a CHO cell transiently 
expressing recombinant NR1/NR2B receptors during application of 30 µM 
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NMDA.  Currents were measured under control conditions, following a 3 min 
application of 4 mM DTT, and a subsequent 30 sec application of 10 µM ebselen.  
DTT typically potentiated currents 1.5-2 –fold, reversible by ebselen.  B: Ebselen 
has no effect on responses from a CHO cell transfected with 
NR1a(c744a,c798a)/NR2B receptors, which lack a functional NR1 redox site.  
Note that DTT does not significantly enhance responses to NMDA, nor does 
ebselen depress responses from baseline.  Similar observations were noted in a 
total of 9 cells expressing wild-type receptors and in 12 cells expressing the 
mutated NR1 subunit.  C: Treatment with the irreversible alkylating agent N-
ethylmaleimide (NEM) causes a permanent potentiation of NMDA-mediated 
whole-cell currents in cortical neurons.  Cells were treated with the reducing 
agent DTT (6 mM; 6 min), and immediately bathed in 300 µM NEM (1 min), 
which substantially prevented further peak current modification by ebselen.  
Changes in the desensitization profile of the response were not reproducible.    
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2.4.3. Ebselen can oxidize cysteine residues in the nicotinic receptor 
 We evaluated whether ebselen could modify another redox-sensitive, 
ligand-gated ion channel.  These experiments were performed to confirm that 
ebselen has no substrate-specificity and that it can readily oxidize cysteine 
residues in unrelated members of the ligand-gated channel superfamily.  
Nicotinic acetylcholine receptors (nAchRs) contain a disulfide bond that lies very 
close to the agonist-binding site of the receptor complex, and reduction of this 
bond abolishes receptor function (Kao and Karlin, 1986; Karlin and Bartels, 
1966).  Oxidation can readily restore activity in these channels.  Carbachol (10 
µM)-induced currents were recorded from Cos-7 cells expressing α2βγδ subunits 
of the nAChR under control conditions and following incubation with 4 mM DTT 
(3 min) or 10 µM ebselen.  As expected, carbachol-induced currents were 
unaffected by ebselen (10 µM) but diminished substantially following DTT 
treatment.  Treatment with 10 µM ebselen after DTT returned currents to near 
control levels (Figure 5).  DTNB (500 µM; 7 min) mimicked the actions of ebselen 
in reversing the effects of DTT (not shown), suggesting that ebselen also acts as 
an oxidant at the nicotinic receptor. 
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Figure 5. Ebselen reverses the effects of DTT on carbachol-induced 
currents in nicotinic acetylcholine receptors. 
Responses to 10 µM carbachol obtained from α2βδε recombinant nicotinic 
acetylcholine receptors transiently expressed in Cos-7 cells were unchanged by 
a three minute incubation in ebselen prior to treatment with DTT.  A subsequent 
3 min treatment with 4 mM DTT substantially diminished carbachol-induced 
currents.  Application of 10 µM ebselen (3 min) returned currents to control 
levels.  Similar results were observed in a total of 6 cells.  
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2.4.4. Ebselen is neuroprotective against NMDA toxicity in vitro 
 We sought to determine whether the interaction of ebselen with the NMDA 
receptor could protect cells from NMDA in a neurotoxicity paradigm.  When 
applied to neurons overnight, 30 µM ebselen showed no intrinsic toxicity (Figure 
6).  Exposure of cultured rat cortical neurons to 100 µM NMDA for 30 min caused 
significant neurotoxicity, reflected as an increase in lactate dehydrogenase 
release from control.  Neuronal toxicity was nearly completely blocked by a co-
application with the NMDA receptor blocker MK-801 (10 µM), confirming the 
NMDA-receptor dependency of the neuronal death observed.  Ebselen (10 µM) 
significantly blocked cell death by approximately 40%, a level of protection similar 
to what had previously been described for PQQ (Aizenman et al., 1992).  In 
these experiments, ebselen was present 30 min prior to NMDA exposure to 
ensure that all the receptors were in the oxidized state before activation.  
Ebselen was also present during and following agonist exposure.  The reason for 
including ebselen following agonist exposure was to eliminate the possibility that 
secondary glutamate release might obfuscate the neuroprotective actions of 
ebselen, as this drug does not antagonize the agonist actions of NMDA per se.  
In order to ensure that ebselen induced neuroprotection by oxidizing the NMDA 
receptor prior to NMDA exposure, we performed additional experiments where 
10 µM MK-801 substituted for ebselen in the post-exposure period.  Under these 
conditions, we observed 43% neuroprotection in the ebselen/post-MK-801 
treatment group, compared to 19% protection in the post-MK-801 only treatment 
group (not shown).  Hence, the complete neuroprotective effects of ebselen in 
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our paradigm are likely mediated by maintenance of the receptors in the oxidized 
state during the secondary release of glutamate.  Ebselen has been shown in 
several systems to abrogate oxidative injury (Mueller et al., 1984; Sies, 1993; 
Wendel et al., 1984).  In fact, a recent study has suggested that ebselen is 
protective against glutamate toxicity in cultured rat cerebellar granule cells by 
acting as an antioxidant (Porciuncula et al., 2001).  Therefore, we evaluated 
whether other, more traditional, antioxidant compounds could also inhibit NMDA 
toxicity under our exposure conditions.  We utilized three different antioxidants: 
Trolox (100 µM), glutathione methyl ester (1 mM), and N-acetylcysteine (1 mM).  
None of these agents provided any measurable protection against NMDA-
induced neurotoxicity (Figure 6B).  
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Figure 6. Ebselen is neuroprotective in an excitotoxicity paradigm. 
A: Neuronal cultures were exposed for 30 min to vehicle (control), 100 µM NMDA 
alone, or in the presence of either 10 µM ebselen or 10 µM MK-801, or ebselen 
alone.  Ebselen was present 30 min prior to, during, and following NMDA 
exposure.  MK-801 was present only during NMDA exposure.  The decrease in 
LDH values from NMDA represents increased neuronal viability, and when 
normalized against total NMDA toxicity, a significant increase in neuronal survival 
was observed in the NMDA + ebselen and NMDA + MK801 treatment groups 
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(***p < 0.001, ANOVA followed by Bonferroni post-hoc tests).  Results represent 
the mean ± S.D. of a representative experiment performed in triplicate.  Similar 
results were obtained in a total of 6 experiments.  B: an additional set of cultures 
were exposed for 30 min to vehicle (control), 100 µM NMDA alone, or in the 
presence of 100 µM Trolox, 1 mM glutathione methyl ester (GSH-ME), or 1 mM 
N-acetylcysteine (NAC).  Antioxidants were present 30 min prior to, during, and 
following NMDA exposure.  No observable neuroprotection was afforded by 
these compounds, nor were they toxic on their own (not shown).  Results 
represent the mean ± S.D. of a representative experiment performed in triplicate.  
Similar results were obtained in a total of 3 experiments. 
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2.5. Discussion 
 We have found ebselen reversed DTT-potentiation of NMDA-induced 
currents in cortical neurons in a concentration-dependent manner.  This effect 
was also observed in recombinant NR1/NR2B receptors expressed in CHO cells, 
but not in cells expressing an NR1a(C744A/C798A)/NR2B mutant receptor, 
which lacks a functional redox modulatory site.  Furthermore, alkylation of native 
receptors also substantially diminished the actions of ebselen.  In addition, 
recombinant nicotinic acetylcholine receptors are modulated by ebselen in a 
manner analogous to other thiol oxidizing agents such as DTNB.  This leads us 
to conclude that ebselen acts as an oxidant at the NMDA receptor redox 
modulatory site, a previously undescribed mechanism of action for this drug.  We 
believe that the final oxidation products of the interaction of ebselen with the 
NMDA receptor are an intramolecular disulfide within the cysteines of the redox 
site itself and an ebselen diselenide product (Schewe, 1995).  This is due to the 
fact that an ebselen-cysteinyl adduct would be structurally similar to the alkylated 
form of the receptor, a conformation that results in a permanent potentiation of 
NMDA-induced currents (Figure 4C; Tang and Aizenman, 1993b).  Whole-cell 
recordings revealed that ebselen seldom decreased baseline NMDA-induced 
currents; that is, the actions of ebselen were mostly apparent after the NMDA 
receptor had been chemically reduced by DTT.  This suggests that under our 
recording configuration, most of the NMDA receptors in the culture system exist 
primarily in the oxidized state.  Although this situation is normally encountered in 
cultured cells that are being rapidly perfused in the recording setup (Aizenman 
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and Reynolds, 1992), it may not be reflective of the redox state of NMDA 
receptors present in neurons in more intact preparations, especially during 
pathophysiological conditions e.g. NMDA exposure or seizure activity; (Sanchez 
et al., 2000).   
 There is a substantial body of evidence linking excessive NMDA receptor-
mediated calcium influx to the widespread neuronal death that occurs in primary 
cultures upon exposure to glutamate (Lee et al., 1999).  Due to the high calcium 
permeability of the receptor, modulation of the receptor by reducing and oxidizing 
agents accordingly modulates calcium influx (Reynolds et al., 1990; Sucher et al., 
1990).  As such, DTT and other reducing agents exacerbate excitotoxic neuronal 
death in culture (Aizenman and Hartnett, 1992; Aizenman et al., 1990), and 
oxidizing agents that act at NMDA receptors are neuroprotective in vitro 
(Aizenman and Hartnett, 1992) and in vivo (Jensen et al., 1994).  We observed 
here that ebselen is neuroprotective against NMDA-mediated neurotoxicity in rat 
cortical cultures.  We propose that the observed neuroprotection induced by 
ebselen in vitro and in vivo (Saito et al., 1998; Takasago et al., 1997; Yamaguchi 
et al., 1998) may be due, at least in part, to modulation of the NMDA receptor 
redox site.   
 We recognize that NMDA receptor oxidation may not fully account for the 
degree of neuroprotection afforded by ebselen in vivo.  For instance, ebselen is 
cardioprotective against ischemia (Maulik et al., 1998).  As NMDA receptors are 
irrelevant to ischemia/reperfusion-induced cardiopathology, this drug probably 
exerts its protective effects through some other function.  However, hypoxic 
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neuronal injury in cortical culture is mediated primarily by activation of NMDA 
receptors (Goldberg and Choi, 1993; Sattler et al., 2000; Sinor et al., 2000).  
Hence, exposure of cortical neurons to NMDA in culture is a good model of 
ischemic injury in this system.  In addition, a recent study suggests that oxidative 
stress may not be a primary component in triggering NMDA-mediated 
excitotoxicity in culture, at least under certain conditions(Rudolph et al., 2000).  
Therefore, it is likely that neuroprotection by ebselen in our model is due primarily 
to a direct interaction of this drug with the NMDA receptor redox modulatory site.  
This is supported by our observation that more typical antioxidants, such as 
trolox, glutathione-methyl ester, and N-acetylcysteine are not neuroprotective 
against NMDA toxicity under identical conditions. 
  NMDA receptors have been implicated in the pathogenesis of neurological 
disorders including stroke, Parkinson’s disease, chronic pain, and epilepsy 
(Dingledine et al., 1999).  Though under heavy investigation as therapeutic 
agents, NMDA receptor blockers have met with limited success in clinical trials 
due to untoward side effects associated with blockade of physiological 
glutamatergic transmission (Lee et al., 1999).  However, redox modulatory 
agents do not cause total receptor function loss, and thus are less likely to 
interfere with normal synaptic transmission.  In fact, PQQ, an NMDA receptor 
oxidant, has been shown to minimize epileptic seizures in vitro and in vivo while 
not significantly affecting LTP in hippocampal slices (Sanchez et al., 2000).  
However, PQQ may be toxic at high doses (Jensen et al., 1994).  In contrast, 
ebselen shows little toxicity in humans at therapeutic doses (Saito et al., 1998; 
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Yamaguchi et al., 1998).  The findings herein may extend the clinical applicability 
of this compound beyond stroke to other disorders where the pathophysiological 
consequences of abnormal glutamatergic transmission have been implicated. 
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3. Interaction between redox and spermine modulation of NR1/NR2A 
cysteine mutant receptors 
3.1. Abstract 
 The NMDA subtype of glutamate receptor is sensitive to reducing and 
oxidizing agents in a subunit specific-manner.  Cysteines 744 and 798 on NR1a 
are responsible for most of the redox sensitivity of NR1a/NR2B, NR1a/NR2C and 
NR1a/NR2D receptors.  However, NR1a(c744a,c798a)/NR2A receptors remain 
fully sensitive to redox modulation.  This has been attributed to additional 
cysteines in the amino-terminal domain (ATD) of NR1 and NR2A.  The 
NR1a(c744a,c798a) mutation has also been shown to alter spermine and proton 
modulation of NR1a(c744a,c798a)/NR2B receptors, and zinc modulation in 
NR1a(c744a,c798a)/NR2A receptors.  This implies that structural determinants of 
redox, spermine, proton, and zinc modulation may be linked in a subunit-specific 
manner.  We sought to determine whether NR1a(c744a,c798a)/NR2A receptors 
would have altered sensitivity to spermine and if spermine could have an impact 
on the remaining ATD redox sensitivity of NR1a(c744a,c798a)/NR2A receptors.  
 We recorded NMDA-induced currents from CHO cells expressing the 
NR1a(c744a,c798a)/NR2A receptor and related mutant NMDA receptors.  We 
observed that 30 µM spermine triggered a rapid but transient potentiation (175%) 
of currents in NR1a(c744a,c798a)/NR2A -expressing cells.  In an attempt to 
determine whether spermine potentiation of NR1a(c744a,c798a)/NR2A receptors 
was functionally related to glycine-independent potentiation by spermine of 
NR1a/NR2B receptors, we tested the sensitivity of NMDA-induced currents to 
spermine in the exon-5 containing NR1b(c765a,c819a)/NR2A construct.  We 
 46 
observed that currents were potentiated by spermine to the same degree as 
NR1a(c744a,c798a)/2A receptors, although the transient nature of spermine 
potentiation was eliminated.  Likewise, we observed that 30 µM spermine 
potentiated NR1a(e181q,e185q,c765a,c819a)/NR2A receptors because 
NR1a(e181) and NR1a(e185) appear to be required for polyamine potentiation of 
NR1a/NR2B receptors.  The ATD redox site mutant NR1a(c79s,c744a,c798a) 
/NR2A  receptor was also sensitive to spermine.  Therefore, we conclude that 
spermine potentiates NR1a(c744a,c798a)/NR2A receptors via a mechanism that 
is different from spermine potentiation of NR1/NR2B receptors. 
 In addition, we observed that the presence of spermine (30 µM) inhibits 
the redox sensitivity of NR1a(c744a,c798a)/NR2A receptors by 38%.  Spermine 
did not interfere with redox sensitivity in NR1a(c79s,c744a,c798a)/NR2A and 
NR1b(c765a,c819a)/NR2A receptors, suggesting that spermine inhibition of 
redox sensitivity is qualitatively different than spermine potentiation of 
NR1a(c744a,c798a)/NR2A receptors.  In conclusion, spermine potentiates 
NR1a(c744a,c798a)/NR2A receptors in a transient manner via a mechanism that 
does not appear to be analogous to spermine potentiation of NR1a/NR2B 
receptors.  In addition, spermine blocks DTT potentiation in NR1a(c744a,c798a) 
/NR2A receptors, but not as effectively in NR1b(c765a,c819a)/NR2A and  
NR1a(c79s,c765a,c819a)/NR2A mutants.  From these findings we conclude that 
structural determinants of spermine and redox modulation of NR1a(c744a,c798a) 
/NR2A receptors are closely associated. 
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3.2. Introduction 
 The NMDA receptor has been intensely studied due to its role in 
neuropathologies such as pain, ischemic stroke, schizophrenia and epilepsy 
(reviewed in Dingledine et al., 1999; Lee et al., 1999).  To date, three gene 
families that encode NMDA receptor subunits have been identified: NR1, a single 
gene product with eight splice variants a-h, NR2, which are comprised of four 
genes, A-D, and NR3 (Chatterton et al., 2002; Dingledine et al., 1999).  
Expression of at least one NR1 and NR2 subunit is required to form functional 
receptors in mammalian heterologous systems.  These "binary" NMDA receptors 
have been studied intensely to determine the functional and pharmacological 
consequences of the subunit composition (Dingledine et al., 1999).  For example, 
NMDA-induced currents are modulated by a number of exogenous and 
endogenous agents, including protons (Traynelis et al., 1998; Traynelis et al., 
1995), zinc (Low et al., 2000; Paoletti et al., 1997; Traynelis et al., 1998), 
phenylethanolamines (Mott et al., 1998), polyamines (Williams, 1997b), and 
reducing and oxidizing agents (Brimecombe et al., 1997; Sullivan et al., 1994) in 
a subunit-specific manner.  Although the structure of the NMDA receptor remains 
unsolved, functional and biochemical studies of mutant NMDA receptors have 
yielded insights as to potential binding sites for these modulatory agents.  
Evidence exists that ifenprodil, an NR2B-sepcific inhibitor, binds with high affinity 
to a site in the amino terminal domain (ATD) of the NR2B subunit (Perin-Dureau, 
2001; Perin-Dureau et al., 2002; Zheng et al., 2001).  Likewise, high affinity zinc 
inhibition of NR2A-containing receptors requires the ATD of NR2A (Fayyazuddin 
et al., 2000; Zheng et al., 2001).  In addition, spermine and redox agents have 
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putative sites of action in the ATD of NR1 (Choi and Lipton, 1999; Masuko et al., 
1999). 
 Spermine has multiple effects on NMDA-induced currents: at high 
concentrations, it can block NMDA receptor function in a voltage dependent 
manner (Williams, 1997b).  At lower concentrations, it potentiates receptor 
function by increasing the affinity of the receptors for glycine.  At saturating 
concentrations of glycine, spermine potentiates NMDA receptors via a voltage 
independent, proton dependent mechanism that is specific to NR1a/NR2B 
receptors, hereafter referred to simply as spermine potentiation.  
 The NR1b splice variant contains exon 5, a 21 amino-acid insert that has 
been shown to mimic the potentiating effects of spermine in NR1a/NR2B 
receptors (Durand et al., 1993; Traynelis et al., 1995).  For example, spermine 
potentiates NR1a/NR2B receptors, whereas the exon-5 containing NR1b/NR2B 
receptors appear already potentiated, and spermine has no further effect 
(Traynelis et al., 1995).  It is thought that exon 5 interacts with two negatively 
charged residues near its splice site, e181, and e185.  These residues may form 
part of a binding site for spermine.  Indeed, NR1a(e181q,e185q)/NR2B receptors 
are largely insensitive to spermine potentiation (Masuko et al., 1999). 
 In addition to spermine, reducing and oxidizing (redox) agents may have 
sites of action in the ATD of NR1.  Redox agents modulate NMDA receptors such 
that reducing agents potentiate and oxidizing agents reverse potentiation of 
NMDA-induced currents (Aizenman et al., 1989).  Mutation of ligand binding 
cysteines in the NR1 subunit of NR1a(c744a,c798a)/NR2B, NR2C, and NR2D 
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receptors nearly abolishes redox sensitivity of these receptors.  However, 
NR1a(c744a,c798a)/NR2A receptors remain sensitive to redox modulation 
(Sullivan et al., 1994).  This remaining redox sensitivity has been ascribed to two 
putative pairs of cysteine residues in the ATD of NR1 and NR2 (Choi et al., 
2001).  Interestingly, it was observed that mutation of the redox site in 
NR1a(c744a,c798a)/NR2B receptors also eliminated spermine potentiation and 
proton sensitivity, implying that redox, spermine, and proton modulation may 
share a common structural mechanism (Sullivan et al., 1994).  Although 
interactions between spermine and redox modulation have been studied in 
NR1/NR2B receptors (Sullivan et al., 1994), potential interactions between 
spermine and redox modulation of NR2A-containing receptors have not been 
investigated.  We report here that although spermine has no impact on the redox 
sensitivity of NR1/NR2A receptors, we observe a novel form of spermine 
potentiation in NR1a(c744a,c798a)/NR2A receptors that is not disrupted by 
perturbations of a putative spermine binding site.  As a result of this finding, we 
sought to determine whether spermine could affect redox sensitivity in 
NR1a(c744a,c798a)/NR2A receptors.  We observed an inhibition of redox 
sensitivity by spermine that depends in part on NR1a(c79), and can be disrupted 
by the presence of exon 5.  
3.3. Methods 
3.3.1. Tissue Culture and Transfection 
 Tissue culture and other reagents were purchased from Sigma (St. Louis, 
MO) unless otherwise noted.  CHO cells were maintained in Ham’s F-12 media 
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containing 10% fetal bovine serum (FBS) and 2 mM L-glutamine.  Cells were 
passaged at a 1:10 dilution when 80% confluent, usually every two days, no 
more than 35 times.  CHO cells were seeded at 2.8x105 cells/well onto 6-well 
plates 24 hours previous to transfection.  The cDNAs for the NR1a, 
NR1a(c744a,c798a), NR2A, NR2B and the positive transfection marker, eGFP 
were previously subcloned in mammalian expression vectors (Boeckman and 
Aizenman, 1994; Boeckman and Aizenman, 1996; Brimecombe et al., 1997).  
The cDNAs for NR1b, NR1b(c765a,c819a), and NR1a(c79a) were a kind gift 
from Dr. F. Zheng (University of Arkansas, Little Rock, AK).  Cells were 
transfected with 5.0 µg total DNA in Opti-MEM medium with 10-15 µL 
LipofectAMINE reagent (Invitrogen, Carlsbad, CA).  cDNAs were transfected at 
the following ratios: NMDAR:GFP 100:1, and 1:3 NR1/NR2A.  Cells were 
trypsinized and replated onto coverslips four hours later, and treated with 30 µM 
ketamine to prevent the excitotoxic cell death that occurs following functional 
receptor expression (Boeckman and Aizenman, 1996).  Recordings were 
obtained 10-30 hours post transfection. 
3.3.2. Electrophysiology 
 Electrophysiological recordings were performed at room temperature 
using the whole-cell configuration of the patch-clamp technique, as described in 
Herin et al. (2001).  Cells were bathed in external solution containing (in mM): 
150 NaCl, 1.0 CaCl2, 2.8 KCl, 10 HEPES, 10 glycine. pH was adjusted to 7.2 
with NaOH.  Electrodes were pulled on either a Sutter P-87 or P-97 electrode 
puller (Sutter Instruments, Novato, CA) to a resistance of 1.5-3 MΩ when filled 
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with internal solution containing (in mM): 140 CsF, 10 EGTA/CsOH, 1 CaCl2, and 
10 HEPES (pH adjusted to 7.2 with CsOH).  Signals were amplified using an 
Axopatch 200B integrating patch-clamp amplifier (Axon Instruments, Foster City, 
CA), filtered using an 80 dB/decade filter at 1 kHz, and digitized at 2 kHz with a 
DigiData 1200b (Axon Instruments) computer interface.  The reference electrode 
was an Ag/AgCl wire bridged with 2 M KCl/1% agarose in PE-90 tubing.  Drugs 
and agonists were applied via a fast perfusion system (Warner Instruments 
Corp., Hamden, CT).  Data were collected and analyzed using commercially 
available software (pCLAMP 8, Axon Instruments). 
3.3.3. Site-directed mutagenesis 
 Site directed mutagenesis was performed using the Quick-change kit 
(Stratagene, LaJolla, CA) according to the manufacturer’s directions.  The 
NR1a(e181q,e185q,c744a,c798a) mutant was obtained by amplification of 
NR1a(c744a,c798) in PRC/CMV as a template with the following primers: 
forward gca gaa gcg ctt gca gac gtt gct gca gga acg gga gtc, reverse gac tcc cgt 
tcc tgc agc aac gtc tgc aag cgc ttc tgc (IDT Technologies, Coralville, IA).  
Methylated parental cDNA was digested with DpnI and transformed by 
electroporation into Top-10 cells (Invitrogen, Carlsbad, CA).  Colonies were 
selected and screened using EcoRI digestion.  Mutations were confirmed by 
sequencing.  
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3.4. Results  
3.4.1. Effects of spermine on NR2A-containing receptors 
3.4.1.1. Spermine does not alter NR1a/NR2A currents 
 NMDA-induced currents were obtained from CHO cells expressing 
recombinant NMDA receptor subunits using whole-cell patch clamp 
electrophysiology.  After establishment of the whole cell configuration, NMDA (30 
µM) was applied to the cell via a fast perfusion system in the presence of 
saturating concentrations of glycine (10 µM).  Currents were measured 
approximately every 30 seconds until the amplitude of the currents stabilized 
(approx. 2-4 minutes).  Cells were then switched into a bathing solution 
containing 30 µM spermine and NMDA-induced currents were elicited at the 
following time points: 10 seconds, 30 seconds, and then every thirty seconds 
thereafter for up to 8 minutes.  
 NMDA-elicited currents in CHO cells transfected with NR1/NR2A subunits 
were unaffected by the presence of spermine (Figure 7A-B).  This lack of effect 
on NR1/NR2A receptors at low concentrations of spermine and saturating glycine 
concentrations is in agreement with previous reports in Xenopus oocytes 
(Williams et al., 1994). 
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Figure 7. Spermine does not alter NR1/NR2A currents. 
A: Representative whole cell currents obtained from CHO cells transiently 
expressing recombinant NR1/NR2A receptors during application of 30 µM NMDA 
in the presence of 10 µM glycine.  Scale bar represents 200 pA and 1 second.  
Currents were measured for 2-3 minutes in external solution prior to application 
of 30 µM spermine.  Time 0 represents the NMDA application obtained 
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immediately prior to application of spermine. Cells were switched into external 
solution containing 30 µM and currents were obtained in spermine-free NMDA 
containing solution. The diagram is meant to illustrate the putative structure of 
the NMDA receptor, and to illustrate various mutations (in this case, none). 
B: Average peak current magnitude represented as a percentage of the time 0 
magnitude.  N=2. 
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3.4.1.2. Spermine transiently potentiates NR1a(c744a,c798a)/NR2A 
receptors 
 In contrast with the results we obtained in NR1/NR2A, we observed that 
30 µM spermine potentiated currents by 173% in CHO cells expressing 
NR1a(c744a,c798a)/NR2A receptors (Figure 8A).  This potentiation was 
transient; as currents returned to control levels within 4.5 min in the continuous 
presence of spermine in 5/5 cells (Figure 8A and B; p>0.8  potentiation at 0 min 
vs 4.5 min).  This suggests that cysteines NR1a(c744) and/or NR1a(c798) may 
mask a spermine binding site, or that a conformational change induced by 
mutation of these residues confers spermine sensitivity to NR1a(c744a,c798a) 
/NR2A receptors.  As spermine potentiation of currents from wild-type NR1/NR2B 
receptors has been well studied (Williams, 1997a), we sought to determine 
whether structural features that are important for spermine potentiation of wild 
type NR1/NR2B receptors were also important for this novel form of spermine 
potentiation in NR1a(c744a,c798a) /NR2A receptors.  
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Figure 8. Spermine transiently potentiates NR1a(c744a,c798a)/NR2A 
currents. 
A: Representative whole cell currents obtained from CHO cells transiently 
expressing recombinant NR1a(c744a,c798a)/NR2A. Scale bar represents 500 
pA and 1 sec.  Currents were measured for 2-3 minutes in external solution prior 
to application of 30 µM spermine.  Diagram is meant to illustrate relative location 
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of mutated residues.  B: Average peak current magnitude represented as a 
percentage of the time 0 magnitude.  Bars represent average +/- SEM (n=5). A 
one-way ANOVA reveals that the difference between the pre-spermine value (-
0.5 min) and 0.5 min are highly significant (p < 0.001). The value at 4.5 min is not 
significantly different from -0.5 min (p > 0.05) and significantly different from the 
point at 0.5 min (p < 0.001). 
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3.4.1.3. Potentiation of NR1a(c744a,c798a)/NR2A by spermine does not 
occur via an NR1 "polyamine site" 
 We were interested in further characterizing the molecular basis for 
spermine potentiation of NR1a(c744a,c798a)/NR2A receptors. As there appears 
to be a spermine binding site in the amino terminal of NR1 which could still be 
present in the spermine-insensitive NR1/NR2A receptors (Masuko et al., 1999), 
we hypothesized that the NR1a(c744a,c798a) mutation could unmask spermine 
potentiation. If this were the case, it would be expected that this NR1 spermine 
binding site might share the same structural determinants as spermine 
potentiation of NR1a/NR2B receptors.  For example, splice variants of NR1 that 
contain exon 5 are insensitive to the potentiating effects of spermine in 
NR1/NR2B receptors (Williams et al., 1994), and so we investigated whether the 
exon 5-containing NR1b(c765a,c819a)/NR2A receptor configuration would be 
rendered relatively insensitive to the potentiating effects of spermine.  
Surprisingly, 30 µM spermine significantly potentiated NMDA-induced currents 
from the cognate exon 5-containing NR1b(c765a,c819a)/NR2A receptors (200%; 
Figure 9A).  This potentiation did not spontaneously reverse as seen in 
NR1a(c744a,c798a)/NR2A receptors, but was rapidly reversible upon washout of 
spermine.  This result argues against the hypothesis that spermine potentiation 
of NR1a(c744a,c798a)/NR2A receptors is analogous to spermine potentiation of 
NR1/NR2B receptors, and suggests that it occurs by a different mechanism.  
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Figure 9. Spermine potentiates NR1b(c765a,c819a)/NR2A currents. 
A: Representative whole cell currents obtained from CHO cells transiently 
expressing recombinant NR1b(c765a,c819a)/NR2A.  Scale bar represents 200 
pA and 1 sec.  Currents were measured for 2-3 minutes in external solution prior 
to application of 30 µM spermine.  Time 0 represents the NMDA application 
immediately prior to application of spermine.  Spermine was applied for five 
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minutes, and then the bathing solution was returned to control.  Diagram is 
meant to illustrate relative locations of mutations and exon 5 (purple subdomain).  
B: Average peak current represented as a percentage of the time 0 magnitude.  
The point at 6 minutes represents current magnitude after 1 minute washout.  
Bars represent average +/- SEM (n=4). A one-way ANOVA reveals that the 
magnitude at -0.5 min and 0.5 min are significantly different (p < 0.05). The value 
at 4.5 min is significantly different from -0.5 min (p < 0.01) and not different from 
the point at 0.5 min (p > 0.05). 
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3.4.1.4. Spermine potentiates NR1a(e181q,e185q,c744a,c798a)/NR2A 
currents. 
 To further evaluate structural determinants involved in spermine 
potentiation of NR1a(c744a,c798a)/NR2A receptors, we tested whether spermine 
could potentiate NR1a(e181q,e185q,c744a,c798a)/NR2A receptors.  The 
negatively charged residues, e181 and e185, located in the proximity of the exon 
5 splice site of NR1, appear to be required for spermine potentiation in 
NR1a/NR2B receptors. Accordingly, alteration of these residues eliminates 
spermine potentiation of NR1/NR2B receptors (Masuko et al., 1999).  Therefore, 
we recorded NMDA-induced currents from NR1a(e181q,e185q,c744a,c798a) 
/NR2A-expressing cells.  Currents were potentiated by spermine (206%) in a 
manner similar to NR1b(c765a,c819a)/NR2A receptors.  These results further 
support the notion that the structural determinants of spermine potentiation of 
NR1 cysteine mutants are not similar to that of glycine-independent spermine 
potentiation of NR1/NR2B receptors.  It is unclear, however whether potentiation 
of NR1a(e181q,e185q,c744a,c798a)/NR2A receptors returns to baseline upon 
continuous spermine exposure, as there was no statistical difference between 
that pre-spermine (-0.5 min), and  3.0 minutes spermine group. 
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Figure 10. Spermine potentiates NR1a(e181q,e185q,c744a,c798a)/NR2A 
currents. 
A: Representative whole cell currents obtained from CHO cells transiently 
expressing recombinant NR1a(e181q,e185q,c744a,c798a)/NR2A receptors.  
Scale bar represents 100 pA and 1 sec.  Currents were measured for 2-3 
minutes in external solution prior to application of 30 µM spermine.  Spermine 
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was applied for three minutes.  Diagram is meant to illustrate relative locations of 
mutations; NR1a(e181q,185q) represented as an x in the ATD of NR1, and the 
redox site mutations in the ligand binding domain of NR1.  B: Average peak 
current magnitude represented as a percentage of the time 0 magnitude.  Bars 
represent average +/- SEM (n=4). A two-tailed T test shows a significant 
difference between the pre-spermine group (-0.5 min) and post-spermine group 
(0.5 min, p = 0.02). A one way ANOVA showed no significance due to variation 
within the groups.  
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3.4.1.5. Spermine potentiates NR1a(c79s,c744a,c798a)/NR2A receptors 
 In an effort to search for potential sites of action of spermine that could 
explain its effects on NR1a(c744a,c798a)/NR2A receptors, we became 
interested in the role of the remaining redox sensitivity of this receptor 
configuration.  We hypothesized that if mutation of the ligand-binding redox site 
uncovers spermine sensitivity, and spermine and redox modulation in 
NR1a(c744a,c798a)/NR2A receptors are interrelated, then the remaining redox 
sensitive cysteines might be important for spermine potentiation.  We thus tested 
the spermine sensitivity of NMDA-induced currents from cells expressing 
NR1a(c79s,c744a,c798a)/NR2A receptors.  This receptor configuration alters a 
putative ATD redox site and abolishes the ligand binding redox site of NR1.  
However, spermine (30 µM) also potentiated NMDA induced currents in 4/4 cells 
an average of 202%.  This is indicative that c79 is not important for spermine 
modulation of NR1a(c744a,c798a)/NR2A receptors.  
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Figure 11. Spermine potentiates NR1a(c79s,c744a,c798a)/NR2A receptor 
function. 
Average peak current magnitude represented as a percentage of the time 0 
amplitude.  Bars represent average +/- SEM (n=3). Bars represent average +/- 
SEM (n=3). A one-way ANOVA  shows a significant difference between pre-
spermine treatment (time 0) and 0.5 minutes incubation on spermine (p < 0.05) 
and the washout group (time 6.5)  is not significantly different from the pre-
spermine group (p > 0.05) 
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3.4.2. Interaction between redox and spermine modulation of 
NR1a(c744a,c798a)/NR2A receptors 
3.4.2.1. Spermine does not alter redox modulation of NR1/NR2A receptors 
 Given the observation that mutation of NR1 redox sites conferred 
spermine sensitivity to an otherwise non-sensitive receptor configuration, we 
evaluated whether spermine could affect the redox properties of NR1/NR2A 
receptors.  We first tested if spermine could alter the redox sensitivity of wild-type 
NR1/NR2A receptors.  To quantify redox sensitivity, we used a protocol very 
similar to that used to measure spermine potentiation: we established the whole 
cell patch clamp configuration, elicited NMDA induced currents every 30 seconds 
until a stable baseline was established, and then switched to a DTT (4 mM)-
containing recording solution.  We measured NMDA-induced currents in DTT at 0 
seconds, 30 seconds, and then every thirty seconds up to 5 minutes (black line; 
figure 12A).  DTT produced an approximate tripling of NMDA receptor current 
amplitudes within 5 minutes A), a result that agrees with previous reports in 
neurons and heterologous expression systems (Arden et al., 1998; Herin et al., 
2001; Tang and Aizenman, 1993b).   
 We then examined whether the presence of spermine would alter the 
redox sensitivity of wild-type NR1a/NR2A receptors.  With 30 µM spermine 
present in all recording solutions, we tested potentiation by DTT in an identical 
manner as in the absence of spermine, again, assuring that currents had 
reached a steady state before switching into DTT containing solutions.  
Potentiation of NMDA-induced responses after a 5 minute application by DTT 
 67 
was similar to that seen in the absence of spermine (Figure 12A; blue line; 
p=0.87).  This is consistent with previous reports (Gallagher et al., 1997). 
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Figure 12. Spermine does not alter DTT potentiation of NR1/NR2A 
currents. 
A: NMDA-elicited currents were recorded from CHO cells transfected with NR1a 
and NR2A subunit cDNA.  After current amplitudes stabilized, cells were 
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switched to external solution containing 4 mM DTT.  NMDA-elicited currents were 
recorded 10 seconds after the onset of DTT, at thirty seconds, and every thirty 
seconds thereafter.  Spermine (30 µM) was present in all solutions in the 
spermine condition.  Points represent the average (+/- SEM) percent of control 
(pre-DTT) current in 9 (control) and 5 (spermine) cells.  B: Bar graph 
representing means+/- S.E.M for currents at 4.5 minutes compared to the 
spermine alone condition at 4.5 minutes (from Figure 7B).  
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3.4.2.2. Spermine inhibits DTT-potentiation of NR1a(c744a,c798a)/NR2A 
receptors 
 Since spermine potentiation of NR2A-contianing receptors appeared to be 
manifested only in NR1a(c744a,c798a)/NR2A-related receptor configurations, we 
investigated whether spermine altered DTT-potentiation in these receptors.  In 
the absence of spermine, we found NR1a(c744a,c798a)/NR2A receptors to be 
sensitive to DTT-potentiation to the same extent as wildtype receptors at 4-5 
minutes (342% ± 43 S.E.M.; Figure 13B black line).  The magnitude and time 
course of potentiation agrees with previous reports in both oocytes (Choi et al., 
2001; Sullivan et al., 1994) and mammalian cells (Brimecombe et al., 1999). 
 In contrast with NR1a/NR2A receptors, when 30 µM spermine was 
present in all recording solutions, DTT-potentiation of NR1a(c744a,c798a)/NR2A 
receptors was decreased by approximately 40% (Figure 13B; blue line). Inhibition 
of redox sensitivity by spermine was compared among varying concentrations at 
1.5 minutes of incubation, and though there appeared to be a trend with maximal 
inhibition at 30 µM, Figure 13C) but this was not statistically significant.  These 
results suggest that spermine can inhibit the effects of DTT, but only when the 
redox modulatory site on ligand-binding domain of NR1 has been abolished.  
This is suggestive of an allosteric interaction between a spermine binding site 
and the redox sites of this mutant, putatively of the ATD redox sites 
NR1a(c79,c308) and/or NR2A(c87,c320).  
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Figure 13. Spermine inhibits DTT-potentiation of 
NR1a(c744a,c798a)/NR2A receptors. 
A: NMDA-elicited currents from CHO cells transfected with 
NR1a(c744a,c798a)/NR2A cDNA.  The bar above the first trace represents the 
duration of application of 30 µM NMDA and is omitted from subsequent traces for 
clarity.  Horizontal dashed lines are for comparison of traces to the peak of the 
control trace.  Traces in black were obtained from cells incubated in external 
solution and then switched into bath solution containing 4 mM DTT. Traces in 
blue represent cells that were exposed to DTT as above, however 30µM 
spermine was present in all solutions.  Schematic represents putative domains 
structure of NR1/NR2A, with redox site mutations represented by an x.  B: Points 
represent the average (+/- SEM) of the following number of cells: black line- 
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NR1a(c744a,c798a)/NR2A control (5); Blue line- NR1a(c744a,c798a)/NR2A + 30 
µM spermine (7).  C: Concentration-response relationship for spermine inhibition 
of DTT potentiation. Points are means ± SEM percent of pre-treatment currents 
at 1.5 minutes.  The first bar represents spermine alone at 1.5 minutes, and the 
subsequent bars are DTT (4mM) potentiation in the respective spermine 
concentrations for the following numbers of cells: spermine alone (5); 0 spermine 
(DTT alone) (4) 10 µM spermine (5); 30 µM spermine (7); 100 µM spermine (3). 
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3.4.2.3. Redox sensitivity of NR1a(c79s,c744a,c798a)/NR2A receptors 
 Structural determinants that are important in spermine potentiation of 
NR1/NR2B receptors are located in the ATD of NR1 (Masuko et al., 1999).  In 
addition, the redox sensitivity of NR1a(c744a,c798a)/NR2A receptors may be 
due to cysteines in the ATDs of NR1 and NR2 (Choi et al., 2001).  As residues 
important for spermine and redox modulation may be situated near each other in 
the ATD of NR1, we hypothesized that the NR1 redox-sensitive cysteines may be 
critical for spermine inhibition of redox modulation of NR1a(c744a,c798a)/NR2A 
receptors.  The NR1a(c79s,c744a,c798a)/NR2A receptor putatively eliminates 
both the NR1 ligand binding domain redox site and disrupts the ATD redox 
sensitivity of NR1 (Choi et al., 2001; Sullivan et al., 1994).  We predicted that 
spermine inhibition of DTT potentiation in NR1a(c79s,c765a,c819a)/NR2A 
expressing cells would be diminished compared to cells expressing 
NR1a(c744a,c798a)/NR2A receptors.  
 We obtained recordings from mutant NR1a(c79s,c744a,c798a)/NR2A 
receptors in an identical experimental paradigm as above.  In the absence of 
spermine, NR1a(c79s,c744a,c798a)/NR2A mutants were potentiated 206% after 
4 minutes incubation in DTT (4 mM).  This potentiation is diminished from 
NR1a(c744a,c798a)/NR2A receptors by 40%.  These results agree with previous 
reports of diminished redox sensitivity in multiple NR1 cysteine mutants (Choi et 
al., 2001).  In addition, the time course of redox potentiation is very similar 
between NR1a(c79s,c744a,c798a)/NR2A and NR1a(c744a,c798a)/NR2A 
receptors (Figure 14B; black line).  
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3.4.2.4. The effects of spermine on DTT potentiation of 
NR1a(c79s,c744a,c798a)/NR2A receptors 
 Spermine (30 µM) inhibited DTT-potentiation of 
NR1a(c79s,c744a,c798a)/NR2A receptors in a manner similar to 
NR1a(c744a,c798a)/NR2a receptors (Figure 14B).  However, inhibition by 
spermine was significantly diminished (22%; Figure 14C).  In addition, the time 
course of DTT potentiation of NR1a(c79s,c765a,c819a)/NR2A receptors was 
very similar in control and spermine conditions.  As spermine inhibition is 
diminished in NR1a(c79s,c765a,c819a)/NR2A receptors, these data support the 
hypothesis that NR1a(c79) plays a role, or at least is permissive, in the 
interaction between spermine and DTT in NR1a(c744a,c798a)/NR2A receptors. 
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Figure 14. Spermine inhibition of DTT-potentiation is diminished in 
NR1a(c79s,c765a,c819a)/NR2A receptors. 
A: NMDA (30 µM) -elicited currents from CHO cells transfected with 
NR1a(c79s,c765a,c819a)/NR2A cDNA. Traces in black represent cells bathed in 
control external solution then switched to 4 mM DTT containing solution. Purple 
traces are cells that were exposed to 30 µM Spermine prior to, and during 
exposure to DTT.  B: Points represent the average (± SEM) of the following 
number of cells: NR1a(c79s,c744a,798a)/NR2A DTT alone (4); 
NR1a(c79s,c744a,798a)2A DTT + spermine (9).  C: Bars represent the mean (± 
SEM) percent inhibition of DTT-potentiation by spermine as follows: % pre-DTT 
current minus %DTT current in spermine for each time point, and then binned 
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from 2 to 8 minutes (*P<0.001 two-tailed t-test).  Schematic represents putative 
domains structure of NR1/NR2A, with cysteine mutations represented by an x. 
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3.4.2.5. Spermine inhibition of redox sensitivity in NR1b(c765a,c819a)/NR2A 
receptors 
 We were interested in investigating whether structural determinants of 
spermine potentiation of NR1a/NR2B receptors were also important in spermine 
inhibition of DTT potentiation.  Given prior evidence that exon 5 mimics the 
actions of spermine (Rumbaugh et al., 2000; Traynelis et al., 1995), we 
hypothesized that the exon 5 containing NR1b(c765a,c819a)/NR2A construct 
would be relatively insensitive to spermine inhibition of redox sensitivity.  
Alternatively, perhaps the spermine -redox interaction in 
NR1a(c744a,c798a)/NR2A resembles spermine potentiation of 
NR1a(c744a,c798a)/NR2A receptors (this report), and is independent of the 
effects of exon 5. 
 It appeared that there was a slight decrease in the DTT sensitivity of the 
NR1b(c765a,c819a)/NR2A receptor, when compared to the 
NR1a(c744a,c798a)/NR2A (compare third bar with first bar, Figure 15), however 
this was not statistically significant.  DTT (4mM) potentiated NMDA-induced 
currents from NR1b(c765a,c819a)/NR2A receptors (second bar) by 252%.  This 
figure is not significantly different from DTT potentiation of 
NR1a(c744a,c798a)/NR2A (fourth bar) receptors in the presence of spermine.  In 
addition, spermine (30 µM) in the recording solutions did not further attenuate 
DTT potentiation of NMDA-induced currents in NR1b(c765a,c819a)/NR2A 
expressing CHO cells (Figure 15).  This suggests that the presence of exon 5 
functionally resembles spermine in modulation of redox sensitivity.  The ability of 
exon 5 to mimic spermine inhibition of DTT potentiation of 
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NR1a(c744a,c798a)/NR2A receptors is suggestive that the actions of spermine 
in this paradigm resembles spermine potentiation of wild-type NR1/NR2B 
receptors as opposed to the novel form of spermine potentiation of 
NR1a(c744a,c798a)/NR2A receptors outlined above.  
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Figure 15. The presence of exon 5 mimics the effects of spermine on 
redox sensitivity. 
A comparison of exon 5-lacking and -containing NMDA receptor redox mutants 
(as denoted below the bar graph) NR1a(c744a,c798a)/NR2A results are shown 
for comparison (from Figure 13; 0 (first bar) and 30µM spermine (third bar)).  
Bars represent means ± S.E.M percent pre-DTT current recorded at 4.5-5 
minutes of incubation in DTT in the following number of cells: 
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NR1b(c765a,c819a)/NR2A + 4 mM DTT (12) and NR1b(c765a,c819a)/NR2A + 
4mM DTT + 30µM spermine (6).  In NR1a(c744a,c798a)/NR2A receptors, N.S. 
denotes that these conditions are not statistically different from each other (One 
way ANOVA, p = 0.22). 
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3.4.2.6. Elimination of a putative site of spermine binding in 
NR1a(e181q,e185q,c744a,c798a)/NR2A receptors induces a new 
phenotype 
 As the presence of exon 5 in the experiment outlined above mimics the 
actions of spermine, this suggests that the actions of spermine may be 
attributable to a putative spermine binding site in the ATD of NR1, analogous to 
spermine potentiation of NR1a/NR2B receptors(Masuko et al., 1999).  It has 
been shown that that residues NR1a(e181) and NR1a(e185) are important for 
spermine potentiation of NR1a/NR2B receptors, and may form a spermine 
binding site in the ATD of NR1 (Masuko et al., 1999).  For this reason, we sought 
to determine whether the NR1a residues e181 and e185 are important in 
spermine inhibition of redox sensitivity in NR1a(c744a,c798a)/NR2A receptors.  
We recorded NMDA-induced currents from CHO cells transfected with the 
NR1a(e181q,e185q,c744a,c798a) construct co-expressed with NR2A.  
Unexpectedly, DTT sensitivity was considerably diminished in this mutant 
compared with NR1a(c744a,c798a)/NR2A at 1.5 minutes DTT potentiates 
NR1a(c744a,c798a)/NR2A receptors 279% (+/-24.2 S.E.M.), but 
NR1a(e181q,e185q,c765a,c819a)/NR2A receptors 139% (+/- 7.1 S.E.M)  (Figure 
12 vs Figure 16; p < 0.0001)  Despite attenuated DTT potentiation in the absence 
of spermine, responses in the presence of spermine were greatly potentiated by 
4 mM DTT.  For example, at 1.5 minutes of DTT application in the presence of 10 
µM spermine, currents were potentiated 480%.  Interestingly, increasing 
concentrations of spermine decreased potentiation by DTT, returning to 227% at 
100 µM (1.5 minutes of DTT incubation).  From these data, we can only 
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determine that NR1a(e181q,e185q,c744a,c798a)/NR2A receptors have a new, 
uninterpretable phenotype that needs to be further characterized.  Thus, we 
cannot use this construct to address the hypothesis that residues NR1a(e181) 
and NR1a(e185) are critical for spermine inhibition of DTT potentiation in 
NR1a(c744a,c798a)/NR2A receptors.  
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Figure 16. DTT and Spermine sensitivity of 
NR1a(e181q,e185q,c744a,c798a)/NR2A receptors 
 Concentration-response relationship for spermine inhibition of DTT 
potentiation of NMDA currents in NR1a(e181q,e185q,c744a,c798a)/NR2A 
expressing cells.  Points are mean (± SEM) percent of pre-treatment currents at 
1.5 minutes.  The first bar represents spermine alone at 1.5 minutes, and the 
subsequent bars are DTT (4mM) potentiation in the respective spermine 
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concentrations.  Means represent the following numbers of cells: spermine alone 
(5); 0 spermine (DTT alone) (8) 10 µM spermine (5); 30 µM spermine (5); 100 µM 
spermine (4). 
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3.4.3. Tricine does not potentiate NMDA–induced currents in our recording 
conditions 
 In our laboratory, the first few currents recorded from CHO cells and 
neurons are largely insensitive to oxidizing agents, but readily potentiated by 
reducing agents.  This potentiation can be reversed by application of oxidizing 
agents, and repeated iterations of reducing and oxidizing agents potentiate and 
decrease currents for the duration of the recording (Arden et al., 1998; Herin et 
al., 2001).  This is highly indicative that in our recording conditions, the 
population of NMDA receptors exists primarily in the oxidized state prior to 
application of reducing agents.  For this reason, we equate sensitivity of NMDA-
induced currents to reducing agents (such as DTT) to their redox sensitivity. 
However, studies by other groups have suggested that DTT potentiation may be 
due to chelation of trace amounts of zinc in recording solutions, as NR2A-
containing NMDA receptors are inhibited by nanomolar quantities of zinc (Paoletti 
et al., 1997).  As zinc contamination of our solutions could compound our results, 
we ascertained whether the heavy metal chelating agent, tricine, could potentiate 
NMDA-induced currents.  Tricine (10 mM) was applied for 30 seconds during a 
1.5 minute application of NMDA (30 µM).  Currents recorded from CHO cells 
expressing NR1a/NR2A, NR1a(c744a,c798a)/NR2A, and 
NR1b(c765a,c819a)/NR2A receptors were insensitive to tricine (Figure 17).  This 
concentration and duration of tricine has been sufficient in potentiating 
NR1a/NR2A receptors expressed in oocytes in the presence of zinc (Choi et al., 
2001; Paoletti et al., 1997).  This confirms previous reports from our laboratory 
using the metal chelator TPEN (Arden et al., 1998).  Therefore, chelation of zinc 
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appears not to be an important consequence of DTT application in this study. 
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Figure 17. Tricine does not potentiate NMDA-induced currents. 
NMDA (30  µM)-induced currents elicited from a CHO cell expressing: 
A: NR1/NR2A receptors, B: NR1a(c744a,c798a)/NR2A, or C: 
NR1b(c765a,c819a)/NR2A receptors.  10 mM tricine applied for 10s during a 30 
second application of 30 µM NMDA does not potentiate responses.  
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3.5. Discussion 
3.5.1. Summary 
3.5.1.1. Spermine potentiates cysteine mutant NR1/NR2A receptors 
 The aim of this study was to characterize effects of spermine on 
NR1/NR2A mutant receptors, and to explore a possible interaction between 
spermine and redox modulation of NR1/NR2A NMDA receptors.  Here we 
confirmed that spermine does not alter NR1/NR2A receptor function; however, 
mutations of redox-sensitive residues in the ligand-binding domain of NR1 
conferred spermine sensitivity to NR1a(c744a,c798a)/NR2A receptors.  This 
novel form of spermine potentiation was not abolished by receptor configurations 
and mutations that eliminate spermine potentiation of NR1a/NR2B receptors.  
This suggests that the mechanism of spermine potentiation of 
NR1a(c744a,c798a)/NR2A receptors differs from that of spermine potentiation of 
NR1/NR2B receptors.  
3.5.1.2. Interaction between spermine and redox modulation of NR1/NR2A 
cysteine mutant receptors 
 We found an additional effect of spermine: spermine (30 µM) inhibited 
DTT potentiation of NR1a(c744a,c798a)/NR2A receptors by approximately 40%.  
Mutation of an NR1 amino terminal cysteine, c79, diminished redox sensitivity in 
NR1a(c79s,c765a,c819a)/NR2A receptors, and relieved spermine inhibition of 
the remaining redox sensitivity of NR1a(c79s,c765a,c819a)/NR2A receptors.  
This indicates that spermine inhibition of redox sensitivity is manifested at least in 
part by the putative ATD redox site of NR1.  Inclusion of exon 5 in 
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NR1b(c765a,c819a)/NR2A receptors mimicked the actions of spermine on redox 
sensitivity, suggesting that spermine may bind to a putative polyamine binding 
site that is also implicated in spermine potentiation of NR1a/NR2B receptors 
(Williams, 1997b).  Attempts to alter this putative binding site in 
NR1a(e181q,e185q,c744a,c798a)/NR2A receptors were uninterpretable.  
Nonetheless, it appears that the structural determinants for spermine inhibition of 
redox sensitivity are more related to spermine potentiation of NR1/NR2B 
receptors than spermine potentiation of NR1a(c744a,c798a)/NR2A receptors.  
From this we conclude that the structural elements that are responsible for redox 
modulation and spermine modulation of NMDA receptors may be intimately 
linked, and/or share important downstream elements.  
3.5.2. Possible interpretations of spermine potentiation of 
NR1a(c744a,c798a)/NR2A receptors 
3.5.2.1. NR1a(c744a,c798a)/NR2A receptors form a de novo spermine 
binding site in the proximity of c744 and/or c798 
 We have shown that mutation of cysteines NR1a(c744) and NR1a(c798a) 
alter NR1/NR2A receptors such that they become sensitive to spermine.  A 
possible interpretation is that NR1a(c744a,c798a) forms a new spermine binding 
site in the proximity of C744 and c798 that is independent of sites previously 
explored in the literature.  Our data do not refute this interpretation: we show that 
spermine potentiation of NR1a(c744a,c798a)/NR2A receptors is not affected by 
the presence of exon 5, nor mutations of positively charged residues near the 
exon-5 slice site (NR1a(e181q,e185q)). However, as spermine is a highly basic 
molecule, most mutations that eliminate spermine effects in other paradigms 
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change acidic residues into neutral or basic residues (Kashiwagi et al., 1996; 
Masuko et al., 1999; Williams et al., 1995).  This implies that negatively charged 
residues are important in the binding and/or actions of the positively charged 
spermine molecule.  In the NR1a(c744a,c798a) mutation cysteines are mutated 
to alanines.  As cysteines are moderately basic residues, and alanines are 
neutral residues, this mutation could be sufficient to create a locally acidic 
environment that could bind spermine directly.  
 Contradictory to this hypothesis, the same mutation has a different 
behavior in NR1a(c744a,c798a)/NR2B receptors.  In this case, spermine 
sensitivity is abolished in an otherwise sensitive receptor configuration (Sullivan 
et al., 1994; Traynelis et al., 1998).  In addition, NR1a(c744a,c798a)/NR2B 
receptors are less sensitive to proton and zinc inhibition (Choi et al., 2001; 
Sullivan et al., 1994; Traynelis et al., 1998).  This evidence suggests that 
NR1a(c744a,c798a) does not form a de novo spermine binding site, but that it 
alters a downstream element of convergent modulatory mechanisms. 
3.5.2.2. NR1a(c744a,c798a)/NR2A uncovers an otherwise masked spermine 
modulatory site: Potential sites in the ATD of NR2A and NR2B 
 While this study focuses on a site in NR1 important for spermine 
modulation of NR1a/NR2B receptors, other potential binding sites for spermine 
have been proposed.  For example, Gallagher et al. (1997) constructed chimeric 
NR2A/NR2B receptors to localize a putative spermine binding site in NR2B.  This 
group identified a negatively charged residue, e201, that when mutated 
diminished polyamine potentiation of NR1a/NR2B(e201r) receptors in a proton-
dependent manner.  In an attempt to determine whether both NR2B(e201) and 
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its adjacent residue NR2B(e200) were important for spermine stimulation, 
Gallagher et al. (1997) measured spermine stimulation of NR2B(e200q,e201n) 
receptors, which retained full polyamine sensitivity.  Interestingly, the sequence 
NR2B(q200,n201) is equivalent to the native NR2A sequence (Gallagher et al., 
1997), implying that spermine may bind at the equivalent site in the ATD of 
NR2A.  It is also interesting to note that both NR2B(e201) and NR2A(q201) are 
analogous to NR1a(e185).  Therefore, it is possible that equivalent spermine 
binding sites exist in the ATD of NR1, NR2A and NR2B, but that NR1/NR2A 
receptors contain structural elements that mask access of polyamines to this site.  
Alternatively, the NR2A environment is non-permissive of transduction of 
polyamine binding to polyamine potentiation.  Our data suggest that NR1a 
cysteines (c744) and (c798) are important in masking either access to a 
spermine binding site or transduction of the effects of spermine binding in 
NR1/NR2A receptors. 
3.5.2.3. Multiple polyamine mechanisms 
 If multiple spermine binding sites exist in NR1a(c744a,c798a)/NR2A 
receptors, each site could have differing effects on NMDA receptor function.  For 
example, our data indicate a complex mechanism for spermine in potentiation of 
NR1a(c744a,c798a)/NR2A.  We have observed a biphasic nature of spermine 
potentiation of NR1a(c744a,c798a)/NR2A receptors: a "fast potentiation" and a 
"desensitizing phase."  Even though the "fast potentiation" is not dependent on 
exon 5 or NR1a(e181) and NR1a(e185), the "desensitizing phase" appears to be.  
This suggests that the mechanism responsible for "fast potentiation" of 
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NR1a(c744a,c798a)/NR2A receptors is different from the mechanism that 
determines the "desensitizing phase."  Because it appears that alteration of the 
ATD of NR1 abolishes the "desensitizing phase" but not the "fast potentiation," it 
is tempting to speculate that a spermine site on NR2A, unmasked by mutation of 
NR1a(c744) and (c798), is responsible for the "fast potentiation" of 
NR1a(c744a,c798a)/NR2A receptors, and that the "desensitizing phase" is due 
to the actions of spermine on a site in NR1a. 
3.5.3. Possible interpretations of spermine inhibition of redox sensitivity 
3.5.3.1. Spermine and DTT potentiation are additive 
 Our results indicate that pre-incubation with spermine inhibits DTT-
potentiation of NMDA-mediated currents in NR1a(c744a,c798a)/NR2A-
expressing CHO cells.  Given the evidence that spermine has a potentiating 
effect on NR1a(c744a,c798a)/NR2A receptor currents, a possible interpretation 
of these data is that spermine had already potentiated currents before DTT 
application.  If there were a maximum, or ceiling, for allosteric potentiation, then 
apparent inhibition of DTT potentiation may represent the additive effects of two 
potentiating agents.  There are several lines of evidence that argue against this 
interpretation.  (1) Spermine inhibition of redox sensitivity is still present after 
spermine potentiation of NR1a(c744a,c798a)/NR2A receptors has returned to 
baseline. DTT is applied only after currents have stabilized in spermine-
containing solutions.  For currents from NR1a(c744a,c798a)/NR2A, this would 
mean that potentiation by spermine alone had reached a steady state close to 
control levels at or beyond 4 minutes of incubation in spermine (Figure 8B).  
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While spermine may still be binding to the site or sites responsible for spermine 
potentiation of NR1a(c744a,c798a)/NR2A receptors, it does suggest that at 4.5 
minutes the contribution of spermine to the overall potentiation is close to zero.  
(2) The mechanisms appear to differ.  Spermine potentiation of 
NR1a(c744a,c798a)/NR2A receptors is not affected by exon 5, and spermine 
inhibition of redox sensitivity is exon-5 dependent.  Therefore, it is unlikely that 
spermine inhibition of DTT potentiation is the consequence of spermine 
potentiation of the same receptors.  (3) DTT does not occlude spermine 
potentiation.  If spermine occludes DTT potentiation by an additive mechanism, 
then one would expect the reverse to be true: DTT would also be expected to 
occlude spermine potentiation.  Preliminary evidence (Figure 18) indicates that 
DTT potentiation does not occlude spermine potentiation, as would be expected 
for a "ceiling effect." 
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Figure 18. DTT potentiation does not preclude spermine potentiation of 
NR1a(c744a,c798a)/NR2A receptors 
Points represent percent pre-DTT current amplitude for 2 cells.  Traces were 
obtained every 30 seconds.  NR1a(c744a,c798a)/NR2A cells were incubated in 
control external solution, and then switched to 4 mM DTT containing external. 
After DTT potentiation stabilized, cells were switched to a solution containing 30 
µM spermine and 4mM DTT.  Note that spermine appears to potentiate 
NR1a(c744a,c798a)/NR2A receptors even after maximal potentiation by DTT.  In 
addition, potentiation of NR1a(c744a,c798a)/NR2A by spermine after potentiation 
by DTT approximates the time course and magnitude of spermine potentiation in 
the absence of DTT.  
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3.5.3.2. Spermine and redox sensitivity share downstream elements 
 Ifenprodil inhibits NR1/NR2B receptors through an enhancement of proton 
inhibition (Mott et al., 1998).  Similarly, it is believed that spermine potentiates 
NR1/NR2B receptors via relief of proton inhibition (Kashiwagi et al., 1997; 
Traynelis et al., 1998).  Therefore, if protons are a common determinant of 
ifenprodil inhibition, zinc inhibition, and spermine potentiation of NR1/NR2B 
receptors, then one would expect the effects of ifenprodil and zinc to be additive, 
and spermine to counteract the effects of zinc and ifenprodil on NR1/NR2AB-
mediated currents.  There is evidence to support this hypothesis (Berger and 
Rebernik, 1999; Traynelis et al., 1998).  Therefore is it possible, if not likely, that 
spermine inhibition of redox sensitivity of NR1a(c744a,c798a)/NR2A receptors is 
due to a shared mechanism of allosteric regulation. 
3.5.3.2.1. Potential Interactions with zinc 
 Previous reports have shown that NR1a(c744a,c798a)/NR2B receptors 
have altered sensitivity to modulatory agents such as zinc, protons, and ifenprodil 
(Mott et al., 1998; Sullivan et al., 1994; Traynelis et al., 1998; Zheng et al., 1998).  
This implies that these modulatory agents share a common downstream element 
or effector in the NMDA macromolecule that ultimately leads to an alteration in 
gating.  It is possible that spermine inhibition of redox sensitivity of 
NR1a(c744a,c798a)/NR2A receptors could be a secondary effect of reduced or 
enhanced modulation of zinc, protons, or a yet unknown modulator of NMDA 
receptor function that may be present in our recording solutions.  
 95 
 For example, Paoletti et al. (1997) observed that NR1/NR2A receptors 
were inhibited by concentrations of zinc in the nanomolar range.  They 
demonstrated that contaminating levels of zinc in recording solutions could 
tonically inhibit NR1/NR2A receptor function.  This group suggested that some of 
the effects of DTT on NR1/NR2A were due to chelation of zinc.  In addition, Choi 
et al., (2001) observed that NR1a(c744a,c798a)/NR2A receptors were less 
sensitive to zinc inhibition than their wild-type counterparts, but only slightly so 
(IC50 12.3 ± 1 nM for NR1a/NR2A vs. 16.2 ± 3.1 nM for 
NR1a(c744a,c798a)/NR2A ).  Therefore it is possible that DTT is acting both as a 
zinc chelator and a disulfide reductant in our studies.  
 Spermine has been shown to relieve zinc inhibition in NR1a/NR2B 
receptors, a mechanism that appears to be intimately related to the proton 
dependence of zinc and spermine modulation (Traynelis et al., 1998).  (Traynelis 
et al., 1998).  If the effects of DTT in our paradigm are compound, then spermine 
could minimize the effects of inhibition by contaminating zinc without altering the 
effects of DTT on disulfide bonds, i.e. spermine relief of zinc inhibition would 
manifest itself as an apparent inhibition of DTT potentiation.  For this to be 
plausible: (1) we would be able to observe tonic modulation of NMDA currents by 
contaminating zinc, and (2) the effects of spermine should be similar in both 
NR1/NR2A- and NR1a(c744a,c798a)/NR2A-mediated currents.  
 To address the first condition, we tested our recording solutions for the 
presence of contaminating levels of zinc.  In our laboratory, chelation of zinc with 
both TPEN (1 µM; Arden et al., 1998) and 10 mM tricine (this report) does not 
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potentiate NR1a/NR2A-mediated currents as would be expected if zinc were 
present at concentrations sufficient to inhibit NMDA receptor function.  In 
addition, reports suggest that DTT-potentiation of NR1/NR2A receptors by 
chelation of zinc is responsible for the fast component of DTT-potentiation (Choi 
et al., 2001; Kohr et al., 1994).  We do not observe this fast component of DTT 
potentiation in NR1/NR2A receptors Figure 12A).  Secondly, we observe no 
spermine potentiation of NR1/NR2A receptors, but a considerable degree of 
spermine inhibition in NR1a(c744a,c798a)/NR2A receptors, which are slightly 
less sensitive to zinc.  Therefore, is seems implausible that spermine inhibition of 
redox sensitivity is a secondary effect due to contaminating levels of zinc. 
3.5.3.2.2. Protons as a common mechanism 
 Another potential modulatory agent that may be important for the 
interaction between spermine and redox sensitivity is protons.  There is strong 
evidence that the mechanism of spermine potentiation in NR1/NR2B receptors is 
due to a relief of proton inhibition (Low et al., 2003; Mott et al., 2003; Traynelis et 
al., 1998; Traynelis et al., 1995).  However, NR1a(c744a,c798a)/NR2B receptors 
are less sensitive to protons than wild-type receptors (Sullivan et al., 1994).  
Thus it appears that mutation of NR1a(c744) and NR1a(c798a) residues renders 
the NR1/NR2B receptor less sensitive to protons.  NR1/NR2A receptors are also 
sensitive to protons (Choi and Lipton, 1999; Low et al., 2000).  However, the 
proton sensitivity of NR1a(c744a,c798a)/NR2A receptors remains unknown.  
Although DTT potentiation does not appear to be functionally dependent on 
protons in neurons (Tang and Aizenman, 1993b), the cysteine mutants 
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NR1a(c744a,c798a)/ NR2B have altered proton sensitivity, implying that at least 
redox sensitivity and proton sensitivity share some structural determinants.  If 
NR1a(c744a,c798a)/NR2A receptors remain sensitive to protons, then 
hypothetically, spermine could shift the pKa of NR1a(c744a,c798a)/NR2A to 
more basic values.  This would result in a more potentiated receptor at pH 7.2 
(our recording conditions).  If DTT were acting in the same manner, the ability of 
DTT to fully potentiate DM receptors through relief of proton inhibition would be 
diminished.  Unfortunately, attempts to characterize pH dependence of 
NR1a(c744a,c798a)/NR2A during the course of this study met with technical 
difficulties.  Therefore, the proton dependence of redox modulation and spermine 
modulation of NR1a(c744a,c798a)/NR2A receptors remains to be investigated. 
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4. General discussion 
 The focus of this dissertation has been to characterize the functional 
effects of reducing and oxidizing agents at the NMDA receptor; specifically the 
ATD redox sites.  Attempts to isolate the ATD redox sensitivity of NR1/NR2A 
receptors by mutation of the ligand binding domain redox site in 
NR1a(c744a,c798a)/NR2A receptors led to the finding that redox site mutations 
affect spermine sensitivity and that spermine affects redox sensitivity in these 
receptors, demonstrating the inherent interrelatedness of modulatory agents with 
putative binding sites within the ATD of NMDA receptor subunits. 
4.1. Relative importance of three redox sites of NR1/NR2A 
 NR1/NR2A receptors putatively contain three active redox sites: a ligand 
binding domain site in NR1 (Sullivan et al., 1994) and two ATD "sites", one in 
NR1, and another in NR2A (Choi et al., 2001).  It is interesting to note that the 
ATD redox "site" in NR1 is present in NR1/NR2B, NR1/NR2C and NR1/NR2D 
receptors also, but appears to be inactive or masked in these receptor 
configurations.  We observe a residual redox sensitivity in 
NR1a(c744a,c798a)/NR2B receptors (Chapter II Figure 3B; Brimecombe et al., 
1997; Herin et al., 2001), however, it remains to be investigated whether this 
residual sensitivity may be due the redox sensitive cysteines in the ATD of NR1.  
Studies suggest that the ATD redox sensitivities of NR1 and NR2A may be the 
dominant redox sites in NR1/NR2A, as the single channel kinetics of 
NR1a(c744a,c798a)/NR2A receptors are indistinguishable from that of wild-type 
NR1/NR2A receptors (Brimecombe et al., 1999).  However, macroscopic time 
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courses of DTT potentiation of NR1/NR2A and NR1a(c744a,c798a)/NR2A 
receptors are considerably different (compare Figure 11A and Figure 12B).  The 
basis of the difference in time course remains to be studied, but it does suggest 
qualitative differences in redox sensitivity between NR1/NR2A and 
NR1a(c744a,c798a)/NR2A receptors.  Our studies suggest that mutation of the 
ligand binding domain redox sites causes the most profound changes in 
NR1/NR2A receptor function, but that alteration of the NR1 redox sensitive 
cysteine NR1a(c79) brought about more subtle changes in function.  Therefore it 
appears that even though the ligand binding domain redox site may not be 
dominant in terms of microscopic redox properties, it does appear to be more 
critical structurally, as mutations of this site have pleiotropic effects.  
4.2. The mechanism of redox sensitivity of ligand binding domain redox 
site vs ATD "sites" 
The structure of the NMDA receptor remains unsolved, therefore so do 
many questions regarding the structural basis for redox modulation.  However, 
the crystal structure of the ligand binding domain of NR1 has been solved, and 
shows that NR1a(c744) and NR1a(c798) are located in the "hinge" region of the 
ligand binding domain (Furukawa and Gouaux, 2003).  The authors of this study 
hypothesize that removal of these cysteines in NR1a(c744a,c798a)/NR2A 
receptors relieves a constraint on clamshell closure and facilitates agonist 
binding (Furukawa and Gouaux, 2003).  As the degree of hinge closure 
correlates with the degree of receptor activation (Jin et al., 2003), this could 
explain the profound effect oxidizing and reducing agents have on NMDA 
receptor function. 
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 Conversely, little is known regarding the localization of the cysteines in the 
ATD.  Although two cysteines in each domain have been shown to be important 
for ATD redox modulation, there is little evidence that they form "pairs."  A model 
of the ATD of NR1 and NR2A based on the crystal structure of a somewhat 
homologous bacterial binding protein, LIVBP, suggests that ATD redox sensitive 
cysteines do not lie across the cleft of the putative ATD clamshell-like structure.  
Therefore, redox modulation of the NMDA receptors by amino terminal domain 
cysteines does not appear to be homologous to modulation by the ligand binding 
domain cysteines.  Although Choi and Lipton (2000) postulate that the 
mechanism of redox modulation of the NR1 and NR2A ATD cysteines is 
intimately related to high affinity zinc inhibition, our results do not concur.  The 
structural mechanism of redox modulation by ATD cysteines remains to be 
determined.  
4.3. The modular versus macromolecular concepts 
 The studies in this dissertation have been based on two opposing ideas of 
the structure-function relationship of the oligomeric NMDA receptor.  A review of 
the literature shows a pervasive concept of the NMDA receptor and other 
ionotropic glutamate receptors as "modular receptors," namely a collection of 
four (or five) subunits that act somewhat independently and contribute additively 
to the total function of the receptor/ion channel.  Another idea is that the 
ionotropic glutamate receptor oligomer is a functional unit, a macromolecule, 
whose behavior cannot be described simply as the sum of its parts.  I will discuss 
both of these concepts as they relate to this dissertation study. 
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4.3.1. Evidence for the modular concept 
 The "modular concept" envisions each subunit of an iGluR as a functional 
unit that contains all the elements necessary to perform the functions of a ligand-
gated ion channel.  This would encompass at minimum a ligand binding element 
and a pore forming element that contains a "gate."  The free energy change of 
ligand binding would be translated from the ligand binding core of each subunit 
into work, which would act to open a subunit-specific gating element.  The 
additive effect of all four gating elements would result in macroscopic ion flux.  
The modular concept resembles most closely the sequential model of allosterism 
of oligomeric proteins as proposed by Koshland et al. (1966), in which a 
conformational change induced by ligand binding in one subunit (in this case, 
hemoglobin) influences the affinity of the neighboring subunit to bind ligand.  The 
degree of influence between subunits depends upon the degree of their 
mechanical coupling.  In Koshland's sequential model of allostery, at one 
extreme there is no mechanical coupling between subunits, and a conformational 
change in one subunit will have no effect on the other.  At the other extreme, that 
in which there is infinite mechanical coupling between elements, ligand binding in 
one subunit would result in a completely concerted allosteric effect, outlined 
further in section  4.3.2.  
 This concept of modularity of ion channels is supported by studies of 
voltage-gated potassium channels.  Gating models based on high resolution 
structures of the KvAP channel suggest that each subunit of the channel contains 
an independent voltage sensor that moves in response to changes in membrane 
voltage.  The independent motion of each of these sensors results in an additive 
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conformational change that leads ultimately to gating of the channel (Jiang et al., 
2003a; Jiang et al., 2003b). 
 For glutamate receptors, the "modular" concept arises historically from the 
observation that the ligand binding domain of iGluRs shares homology with 
bacterial binding proteins (Nakanishi et al., 1990).  This suggested that iGluRs 
subunits could be "pieced together" evolutionarily from functionally distinct 
elements such as a potassium channel-like pore element, and bacterial amino 
acid binding protein-like ligand binding elements and modulatory ATD elements 
(reviewed in Wo and Oswald, 1995). 
4.3.1.1. Ligand binding domains of ionotropic glutamate receptors appear 
to be modular elements 
 The most extensively studied element of the glutamate receptor ion 
channels is the ligand binding element.  This element is contained in a globular 
protein domain (ligand binding domain; S1S2) that is somewhat conserved 
among all glutamate receptors (Dingledine et al., 1999; Nakanishi et al., 1990; 
Nakanishi and Masu, 1994).  This domain appears to function somewhat 
independently of the rest of the protein structure, as ligand binding domain 
constructs retain ligand binding activity when expressed in isolation.  For 
example, constructs of the ligand binding domain of NR1 have been expressed in 
e. coli and bind the competitive antagonist [3H]MDL105,519 with high affinity 
(Ivanovic et al., 1998; Neugebauer et al., 2003).  A ligand binding domain 
construct of the AMPA receptor subunit GluR2 (Armstrong and Gouaux, 2000; 
Armstrong et al., 1998; Jin and Gouaux, 2003) and mutants thereof (Armstrong 
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et al., 2003) have been shown to bind agonists in isolation from the full length 
receptor. 
 In addition, domain-swapping studies suggest that the ligand binding 
domain is a functional unit.  Ligand binding domains of kainate receptors can be 
exchanged with those of non-functional glutamate receptors to produce 
functional receptors with an agonist  EC50 resembling that of the kainate receptor 
(Strutz et al., 2002; Villmann et al., 1997).  Glycine dependent desensitization in 
NMDA receptors can be transferred from the desensitizing NR2A-conataining 
receptors to non-desensitizing NR2C-conatining receptor by exchanging the 
amino-terminal domain and a small segment just N-terminal to the first 
transmembrane domain (Villarroel et al., 1998).   
4.3.1.2. Amino terminal domains of ionotropic glutamate receptors could be 
modular 
 It appears that the ligand binding domain retains its function separately 
from the rest of the receptor subunit.  Is this true of the ATD?  Whether the ATD 
retains the ability to bind agents such as ifenprodil of zinc in isolation from the 
rest of the receptor subunit remains to be determined.  However, an AMPA 
receptor construct lacking the amino terminal domain is expressed and fully 
functional (Pasternack et al., 2002), suggesting that the ATD is not required for 
AMPA receptor function.  Conversely, this appears not to be true of NR1 NMDA 
receptor subunits, as attempts to express NR1 receptors lacking the amino 
terminal domain have been unsuccessful thus far (Meddows et al., 2001).  
The subunit dependence of NMDA receptor modulatory agents initially led 
investigators to assume that if, for example, a modulatory agent is specific for 
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NR2A, that its site of binding and/or action must be present on the NR2A subunit.  
This approach has proven to be fruitful in determining binding sites in the ATD of 
NR2 subunits for zinc and ifenprodil (Fayyazuddin et al., 2000; Paoletti et al., 
1997; Paoletti et al., 2000; Perin-Dureau et al., 2002; Zheng et al., 2001).  
Further, Perin-Dureau et al. (2002) have demonstrated that ifenprodil inhibition of 
NMDA receptors, specific for NR2B-containing receptors, can be transferred to 
NR2A-containing receptors by swapping the ATDs of the respective NR2 
subunits.  This suggests that the ATD of NMDA receptors may also function in a 
modular manner.  A modular nature of NMDA receptor modulation would predict 
that the conformational change induced by binding of agents to the ATD of NR2 
would be more likely to affect ligand binding in same subunit.  In support of this, 
(Zheng et al., 2001) provide evidence that zinc and ifenprodil binding to NR2A 
and NR2B, respectively, caused an allosteric intradomain interaction with the 
glutamate binding site.  
4.3.1.3. Modularity of gating 
 A functional study designed to determine the subunit stoichiometry of 
ionotropic glutamate receptors suggests that ligand binding and "gating" may be 
linked in a subunit-specific manner (Rosenmund et al., 1998).  These 
investigators obtained single channel recordings from HEK cells expressing 
GluR3/GluR6 cDNA.  Cells were bathed in a high affinity antagonist, and then 
switched to a solution containing saturating concentrations of agonist.  Under 
these conditions, the authors observed subconductance levels that "stepped" 
from no current to full current through three steps.  Models of waiting times 
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predicted that GluR3/GluR6 iGluRs require two ligand binding sites to be 
occupied for activation of the ion-conducting pore, and that further occupation of 
each ligand binding site results in a discrete conductance.  Assuming one ligand 
binding site per subunit, this is suggestive that occupation of the ligand binding 
site in each subunit it results in a subunit-specific gating event and that 
occupation of each binding site is independent of the others.  
 The evidence outlined above favors a concept of ionotropic glutamate 
receptors as being modular proteins in which structural domains of each subunit 
may be specialized to perform an independent function, whether it be gating, 
ligand binding or allosteric modulation of the receptor, and that these functions 
are not coupled tightly to other domains of the macromolecule.  This would 
require that the degree of mechanical coupling between domains is fairly low.  A 
minimum degree of coupling would require that ligand binding domains must be 
coupled to the gate, and that regulatory domains coupled to the ligand binding 
domain in order to translate ligand binding into ion flux.  However, this concept is 
limited in its ability to explain the physiological functions that have been 
described in the literature.  
4.3.2. Evidence for the macromolecular concept 
 An opposing view of the "modular concept" of ionotropic glutamate 
receptor structure is a view in which the allosteric sites in the receptor are all 
tightly coupled such that the entire molecule functions as a unit.  In this view, a 
conformational change that occurs, for instance, in the c-terminal region of NR1 
would elicit a conformational change that not only included the NR1 C-terminal, 
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but also the ATD of NR2, a concerted conformational change throughout that 
entire macromolecule.  This view resembles the Monod-Wyman-Changeaux  
model of allostery in hemoglobin (Monod et al., 1965), in which the conformation 
of a subunit in an oligomer is constrained by the conformation of the other 
subunits.   
 Supporting the macromolecular concept of ionotropic glutamate receptors 
are a myriad of studies that show allosteric interaction not only between subunits, 
but from intracellular binding sites to extracellular binding sites.  These allosteric 
interactions suggest that occupation of a binding site causes a more global 
conformational change that may modify the molecular behavior of sites that are 
distant from the binding site.  
4.3.2.1. Intersubunit interaction between co-agonist sites 
 NMDA receptors are activated by the binding of coagonists glutamate and 
glycine to sites on NR2 and NR1, respectively (Dingledine et al., 1999).  The 
affinity of the NMDA receptor for glycine depends on the NR2 subunit that it is 
co-expressed with.  The difference in glycine affinity of NR1/NR2C is 
approximately 10 fold higher than that of NR1/NR2A receptors (Laurie and 
Seeburg, 1994).  Accordingly, a radioligand has been developed that can 
distinguish between NR1 glycine sites when bound to various subunits (Honer et 
al., 1998).  This suggests that the properties of glycine binding site are not 
independent, but highly dependent on the environment provided by the NR2 
subunit.  
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 In addition, the glutamate and glycine binding sites are coupled 
allosterically in a negative manner such that binding of glutamate to its site in 
NR1 decreases the affinity of the NMDA receptor for glycine and vice versa 
(Lerma et al., 1990; Nahum-Levy et al., 2002).  A recent report suggests that a 
linker in the ATD of NR2 may account for this inter subunit interaction (Regalado 
et al., 2001).  Therefore, it appears that the binding of ligand in one domain 
causes a considerable change in the environment of the neighboring subunit, at 
least for NMDA receptors.  This suggests a high degree of cooperativity between 
subunits, which would support the idea that the ionotropic glutamate receptors do 
not function as a collection of functional domains.  
4.3.2.2. Intersubunit interactions in zinc and ifenprodil inhibition of NMDA 
receptors 
 Intersubunit allostery is not limited to the ligand binding domains. Subunit-
specific modulation allosteric modulation demonstrates a highly interrelated 
nature of the subunits.  Both ifenprodil and zinc inhibit NMDA receptor function in 
a subunit specific manner via binding sites in the NR2 subunit (Fayyazuddin et 
al., 2000; Low et al., 2000; Paoletti et al., 2000).  However, inhibition by both of 
these agents is affected by structural elements located in the NR1 subunit.  For 
zinc, the presence or absence of exon 5 on NR1 determines the sensitivity of 
NR1/NR2A receptors to high affinity zinc inhibition (Traynelis et al., 1998).  
Additionally, almost all mutations in NR1 previously shown to affect proton 
sensitivity affect zinc inhibition in parallel (Traynelis et al., 1998).  Ifenprodil 
inhibition also is affected by mutations in the NR1 subunit. One mutation, 
NR1a(d130n) reduced the sensitivity of NR1/NR2B receptors by 500 fold 
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(Masuko et al., 1999).  As mentioned in the introduction, alteration of the ligand-
binding domain redox site in NR1 abolished ifenprodil inhibition in 
NR1a(c744a,c798a)/NR2B receptors (Sullivan et al., 1994).  This is highly 
suggestive that structural elements in the NR1 subunit are required for 
"transduction" of ifenprodil or zinc binding in the ATD of NR2 to the gating 
element, further arguing against a modular idea of ionotropic glutamate receptor 
function. 
4.3.2.3. "Distant" allosteric interactions 
 Protein kinases, interacting proteins, and other intracellular agents 
modulate glutamate receptor function.  In general, ionotropic glutamate receptor 
function is potentiated by phosphorylation (reviewed in Dingledine et al.,1999).  
Interestingly, evidence suggests that the tyrosine kinase src potentiates 
NR1/NR2A receptors by relief of high affinity zinc inhibition (Xiong et al., 1999; 
Yamada et al., 2002; Zheng et al., 1998).  As src acts intracellularly, and zinc has 
a binding site likely located in the ATD of NR2A, it appears that conformational 
changes induced in an intracellular domain are not independent of the relatively 
"remote" ATD.  
4.3.3. Evidence from this study: modular or macromolecular? 
 This dissertation adopts the modular view when forming hypotheses about 
redox and polyamine modulation of NR1 receptors.  The hypothesis that a 
polyamine binding site may have an allosteric effect on the redox modulation of 
the same domain assumed a modular nature of the ATD of NR1.  In the extreme, 
this view imagines that the ATD of NR1 can bind multiple modulators, convert the 
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conformational changes from each binding event into a domain-specific 
conformational change, and then communicate the sum total of this 
conformational change to the rest of the subunit, thereby allosterically affecting 
the function of the channel.  This assumption is in opposition to the idea that 
binding of spermine to a site in the ATD of NR1, or the breaking and formation of 
a cysteine bond contained on NR1, would change the conformation of the entire 
NR1/NR2A molecule in a concerted manner.  
 With this assumption, we expected that mutation of NR1(c79) in 
NR1a(c79a,c765a,c819a)/NR2A receptors (section 3.4.2.4) would abolish the 
effect of spermine on DTT potentiation.  Because we hypothesized that the 
putative spermine binding site and NR1(c79) were in the same domain, the 
modular view would assume that most of the redox sensitivity affected by 
spermine was that of the NR1(c79)-containing redox sensitivity.  Our results 
show that mutation of NR1(c79) did indeed diminish spermine block of redox 
sensitivity, but it did not eliminate it completely.   This  implies that spermine had 
an effect on the remaining redox sensitivity in the NR2 subunit.  This does not 
support the underlying assumption that a spermine-redox interaction would be 
predominantly intradomain.  
Our finding that mutation of cysteines in the ligand-binding domain of NR1 
converted a spermine insensitive receptor (NR1/NR2A) into a spermine sensitive 
receptor (NR1a(c744a,c798a)/NR2A) also supports the macromolecular concept.  
The binding site of spermine in potentiation of NR1a(c744a,c798a)/NR2A 
receptors is unknown.  While it is possible that the NR1a(c744a,c798a)/NR2A 
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mutation causes a local conformational change that creates a spermine binding 
site (as discussed in section 3.5.2.1), it is also possible that the 
NR1a(c744a,c798a)/NR2A receptor is permissive for ATD spermine binding sites 
that are masked in NR1/NR2A receptors.  This would support the idea that a 
global conformational change occurs upon mutation of NR1a(c744) and 
NR1a(c798).  Indeed, NR1a(c744a,c798a)/NR2A receptors are less sensitive to 
high affinity zinc inhibition (Choi et al., 2001), and NR1a(c744a,c798a)/NR2B 
receptors are insensitive to spermine potentiation and proton inhibition (Sullivan 
et al., 1994).  The sites of action of these modulatory agents all appear to be 
discrete from the location of NR1a(c744) and NR1(c798a) and imply that a global 
conformational change occurs when these residues are altered.  This could also 
explain the significant change in time course of redox sensitivity observed 
between NR1a(c744a,c798a)/NR2A and NR1/NR2A receptors.  
 It is of note that NMDA receptors appear to be far more complex than 
other ionotropic glutamate receptors.  While studies revealing previously 
unknown allosteric modulators of AMPA and Kainate receptors are emerging e.g. 
(Mott et al., 2003), it appears that AMPA/Kainate receptors are less highly 
modulated than NMDA receptors.  The recent crystal structure of the ligand 
binding domain of NR1 reveals a considerable difference in "loop 1", a cysteine-
rich element, between the ligand binding domains of NR1 and the AMPA 
receptor subunit GluR2 (Furukawa and Gouaux, 2003).  Interestingly, Regalado 
et al. (2001) suggested that this loop may be the site of interaction between 
glutamate and glycine binding domains in NR2 and NR1, respectively, and could 
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explain the physical basis of the allosteric interaction between glutamate and 
glycine.  This leads to the postulation that the structure of NMDA receptors may 
afford a higher degree of mechanical coupling that AMPA and Kainate receptors, 
thereby giving NMDA receptors a more "macromolecular" nature than the 
relatively "modular" AMPA and Kainate receptors. 
4.4. The usefulness of site directed mutagenesis as tool to uncover 
structure-function relationships of ion channels 
 The central dogma of structural biology is that the three dimensional 
structure of a protein determines its function.  The technique of site-directed 
mutagenesis has been used extensively to estimate protein structure; specifically  
to determine the importance of a certain residue, to probe for binding sites, to 
determine the topology of the protein, and even to explore tertiary and quaternary 
structure.  Determination of structure-function relationships of ion channels by 
site-directed mutagenesis has been widely used, with varying results.  For 
example, over 100 mutants have been tested to determine the structure of the 
ligand binding domain in ionotropic glutamate receptors (Dingledine et al., 1999).  
Mapping these residues onto the crystal structure of the GluR2 ligand binding 
domain (Armstrong and Gouaux, 2000) reveals that all but one of the residues 
that contact the ligand are predicted by site directed mutagenesis.  Thus site 
directed mutagenesis can be a useful tool.  However, sometimes site directed 
mutagenesis results can be misleading.  For example, it was predicted by site 
directed mutagenesis that the selectivity filter of potassium channels was formed 
by pi orbitals of aromatic residues (Kavanaugh et al., 1991).  When the crystal 
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structure for KscA was solved, this view proved to be inaccurate (Doyle et al., 
1998).   
 While site-directed mutagenesis may accurately predict ligand binding as 
measured by channel function, mutation of modulatory sites may involve more 
complex allosteric changes within the structure of the protein.  Residues that alter 
modulation of NMDA receptors may be involved in forming a binding site for the 
modulatory agent, but alternatively, could be important in transduction of 
conformational changes elicited by binding.  In addition, these residues may 
instead (or in addition to) be critical for oligomerization.  In this case, mutation 
may disrupt the quaternary structure of the protein, and have non-specific effects 
on modulation of channel function.   
We have observed that the quadruple mutation in 
NR1a(e181q,e185q,c765a,c819a)/NR2A  generated functional receptors, but that 
these receptors had unusual properties of modulation.  The 
NR1a(e181q,e185q,c765a,c819a)/NR2A mutant abolished sensitivity to the 
reducing agent DTT (Figure 16).  This would imply that NR1 glutamates 181 and 
185 are important for redox sensitivity of NR1a(c744a,c798a)/NR2A receptors.  
However, this sensitivity is possibly restored in the presence of spermine (Figure 
16).  It is possible that glutamates 181 and 185 are important for the transduction 
of the conformational change elicited by redox agents.  Alternatively, this 
mutation could concomitantly abolish redox sensitivity and increase the 
sensitivity of this receptor to spermine.  It is also possible that these negatively 
charged residues are important for the localized charge of residues permissive of 
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redox modulation, but this wouldn't explain why the presence of a positively 
charged molecule (spermine) could restore sensitivity.  The results of the 
NR1a(e181q,e185q,c765a,c819a)/NR2A mutant studies are uninterpretable and 
an example of why caution should be used in interpreting site-directed 
mutagenesis studies. 
4.5. Summary 
 In summary, modulation of NMDA receptor function is the result of 
complex interactions between modulatory agents that are highly interdependent.  
This study focused on modulation of NMDA receptors by reducing and oxidizing 
agents and an interaction of redox modulation with spermine modulation.  
Although the structural bases for this interaction require higher resolution 
structural data to fully be understood, this study adds to the knowledge base with 
regards to sites of action and important structural determinants of modulatory 
agents. 
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